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ABSTRACT  
Hereditary non-polyposis colorectal cancer (HNPCC) is a dominantly inherited 
cancer syndrome. Germline mutations in a four different mismatch repair (MMR) 
genes, MSH2, MSH6, MLH1, and PMS2, are convincingly associated with 
HNPCC. Germline mutations in MSH2 and MLH1 genes are the most common 
and they are mainly identified in classical HNPCC families, which display the 
typical clinical and molecular features of the syndrome, such as early age of onset 
and high microsatellite instability (MSI) in tumor cells. High MSI is a consequence 
of a defect in DNA mismatch repair and the pathogenicity of germline mutations 
in HNPCC is thus linked to the malfunction of MMR. MSH6 is the third most 
common suscebtibility gene in the HNPCC syndrome, but the pathogenicity of 
MSH6 mutations often remains questionable, because these mutations are mainly 
linked to putative HNPCC families with a late age of onset, few affected family 
members, an atypical tumor spectrum with an excess of endometrial cancers and 
a lack of or low MSI phenotype. A significant proportion of all mutations 
identified in MSH6 are missense alterations and their pathogenicity is often 
difficult to determine without functional studies. 
 
Our main aim was to elucidate whether and how MSH6 missense mutations 
cause cancer susceptibility. We clarified the functional consequences of eleven 
potentially pathogenic MSH6 mutations which were found in putative HNPCC 
families. We also tried to find out which one of the two MMR gene mutations, one 
in MSH2 and one in MSH6, found in a colon cancer patient could primarily 
underlie the cancer susceptibility in the patient’s family. We studied the 
expression level of the protein variants, heterodimerization of MSH6 variants 
with MSH2 and the functionality of these MutSα complexes in a human cell-
based in vitro MMR assay. 
 
Ten out of eleven MSH6 protein variants were able to interact with wildtype 
MSH2 protein and they were also able to correct mismatches in the in vitro 
mismatch repair assay. One of those, MSH6-G566R, carrying a mutation in the 
MSH2-MSH6 interaction region, had a similar repair activity to wildtype protein 
but was poorly expressed suggesting problems in its stability. Only one mutation, 
MSH6-E1193K, showed marked impairment of heterodimerization with MSH2 
and mismatch repair capability. This mutation occurred in two women with 
endometrial cancer (ages of onset 59 and 60 years) without any family history of 
cancer suggestive of HNPCC. Neither of the two MMR gene mutations found in a 
single colon cancer patient showed MMR deficiency. However, our results do not 
exclude the possible compound pathogenicity of the two mutations. 
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Our results are clinically relevant since they demonstrate that in stable in vitro 
circumstances, when the amounts of the proteins were sufficient for repair, 10 out 
of 11 tested MSH6 mutations were MMR-proficient. This finding, together with 
clinical data of the patients and their families, leads to the conclusion that many 
or most missense changes in MSH6 are clinically innocent. Some missense 
alterations, such as MSH6-E1193K, which lead to impaired mismatch repair, are 
likely to be clinically significant, but have low penetrance. However, it is also 
possible that while the typical HNPCC syndrome is linked to malfunction of the 
MMR reaction, the pathogenicity of mutations in putative HNPCC families is 
linked to other biochemical events preceding the repair reaction, e.g. shortage of 
functional protein. Especially in situations where cosegregation of mutation and 
disease phenotype cannot be studied, a functional test is needed to confirm that 
cancer susceptibility in a family is linked to a found mutation. 
 
In HNPCC-related tumors, the inactivation of MMR genes is an early event in 
tumorigenesis. DNA MMR deficiency then leads to the inactivation of many 
growth-regulatory genes that contain coding nucleotide repeats. This promotes 
activation of pathways which lead to the expression of genes that favor cell 
growth. The molecular basis of organ selection in HNPCC tumorigenesis is poorly 
understood, and it is not known why activation of the mutator pathway occurs 
more commonly in the colon and endometrium than in other organs. 
Overactivation of the Wnt signaling pathway has been shown to play an 
important role in tumorigenesis of certain carcinomas. Abnormalities in APC or β-
catenin, the main components of this pathway, are common in colorectal 
carcinomas (CRCs), including HNPCC-related CRCs, as well as in sporadic 
endometrial carcinomas (ECs), but HNPCC-related ECs are poorly characterized 
in this regard. We compared the expression of APC and β-catenin in 31 CRCs and 
19 ECs from HNPCC patients carrying the same predisposing mutations in either 
MLH1 or MSH2. Nuclear accumulation of β-catenin was judged to represent 
overactivation of the Wnt pathway and this overactivation was seen in 84% 
(26/31) of CRCs as compared to 53% (10/19) (P=0.02) of ECs. Accumulation of β-
catenin was shown to be independent of its negative regulator, APC, in a large 
fraction of CRCs and even more so in ECs. In conclusion, we provide the first 
evidence that APC/β-catenin abnormalities are involved in HNPCC-related 
endometrial tumorigenesis. APC/β-catenin abnormalities in HNPCC-related ECs,  
although significant, are less frequent than in HNPCC-related CRCs even when 
the same mismatch repair gene mutation predisposed to both tumor types. 
 
 10
INTRODUCTION 
Hereditary non-polyposis colorectal cancer (HNPCC) syndrome is the most 
common form of hereditary colon cancers (Lynch and de la Chapelle 2003). In 
addition to colorectal cancer (CRC), HNPCC families often display an excess of 
extracolonic cancers, especially endometrial cancer (EC) (Aarnio et al. 1999). Early 
age of onset, numerous affected family members and multiple primary tumors are 
characteristic features of HNPCC, as in many other hereditary cancer syndromes. 
 
The genetic basis for HNPCC became evident in the early 1990s with the 
demonstration that a germline mutation in a DNA mismatch repair (MMR) gene 
results this syndrome (Aaltonen et al. 1993; Peltomäki et al. 1993). DNA MMR is 
one of several repair mechanisms that are required to maintain genomic stability 
in prokaryotic and eukaryotic cells. Malfunctions of the MMR system create 
genetic instability. This instability is mainly observed in microsatellite sequences 
and is called microsatellite instability (MSI) (Ionov et al. 1993; Thibodeau et al. 
1993). Most microsatellite repeats in the genome are located within noncoding 
sequences and are thus considered to be silent. However, in MSI carcinomas, 
many growth-regulatory genes show instability in microsatellites within their 
coding regions. The tumor cells of HNPCC patients usually display a high MSI 
phenotype. Moreover, sporadic counterparts of carcinomas included in the 
HNPCC tumor spectrum may also show a high degree of MSI (Helland et al. 
1997; Boland et al. 1998; Gurin et al. 1999). In these tumors, the MSI phenotype 
mostly results from the epigenetic silencing of MMR genes and more rarely from 
somatic MMR gene mutations (Liu et al. 1995; Kane et al. 1997; Veigl et al. 1998; 
Esteller et al. 1999; Kuismanen et al. 2000). 
 
The MMR genes MLH1 and MSH2 account for the majority of HNPCC cases. 
Germline mutations in these genes are mainly associated with classical HNPCC 
families, which display the typical clinical features of the syndrome and a high 
MSI phenotype in tumor cells (Liu et al. 1996, Nyström-Lahti et al. 1996). MSH6 is 
the third most common suscebtibility gene in HNPCC syndrome accounting for 
7% of reported mutations found in the HNPCC kindreds (http://www.nfdht.nl).  
MSH6 protein forms a heterodimeric complex with MSH2 protein and this 
complex recognizes base-base mismatches and one basepair insertion-deletion 
loops (Acharya et al. 1996; Genschel et al. 1998). A significant proportion of all 
mutations identified in the MSH6 gene are missense mutations of unknown 
significance. Since MSH6 missense mutations are often associated with small and 
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putative HNPCC families (Kolodner et al. 1999; Wijnen et al. 1999; Wu et al. 1999; 
Parc et al. 2000; Wagner et al. 2001), which lack the typical molecular and clinical 
features of the syndrome, their pathogenicity is impossible to evaluate without a 
functional test. To date, only a yeast-based functional assay has been used to 
study the pathogenicity of MSH6 missense mutations derived from HNPCC 
patients (Kolodner et al. 1999). Here, we used a human cell-based in vitro 
mismatch repair assay to clarify their pathogenicity (Lahue et al. 1989; Holmes et 
al. 1990). Previously this assay has been successfully used to study the 
pathogenicity of MLH1 missense mutations (Nyström-Lahti et al. 2002; Raevaara 
et al. 2002). By complementing cells which were MSH6-deficient (MSH6-/-) with 
overexpressed mutated MSH6 protein, and by using heteroduplex-DNA with a 
base-base mismatch as a substrate, we could study the MMR capability of MSH6 
variants. With the same assay we also tried to clarify which one of the two 
mismatch repair gene mutations found in a single colon cancer patient could 
primarily underlie the cancer susceptibility in the family. Our findings are 
clinically relevant since they provide essential data concerning the pathogenicity 
of MSH6 missense mutations. 
 
The predisposition to HNPCC is inherited in an autosomal dominant fashion. 
Consistent with that, genetically predisposed individuals carry one mutant and 
one wildtype copy of a given MMR gene in their normal tissue, and only if the 
wildtype copy is also inactivated does the cell become MMR-deficient. This causes 
the activation of the mutator pathway, which leads to genomic instability and 
cancer formation. The reasons why bi-allelic gene inactivation occurs more 
frequently in the colon and endometrium than in other organs are not yet 
understood. We had a great opportunity to clarify the tumorigenesis in these two 
organs by using unique tumor material from HNPCC patients who shared the 
same germline mutation in a MMR gene. In recent years, the Wnt signaling 
pathway has received considerable attention because it has been reported to play 
an important role in the formation of certain tumors, especially colorectal cancer. 
The Wnt signaling pathway has been shown to be overactivated in 65% of 
HNPCC-related CRCs (Miyaki et al. 1999). However, until now the role of this 
signaling pathway had not been determined in HNPCC-related ECs. Here, the 
question of organ specificity and the role of the Wnt signaling pathway in ECs 
was addressed by studying APC and β-catenin expression patterns in colorectal 
and endometrial tumor samples from HNPCC patients carrying the same 
predisposing mutations. 
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REVIEW OF THE LITERATURE 
HEREDITARY NON-POLYPOSIS COLORECTAL CANCER SYNDROME 
Hereditary cancer 
In Finland, one in four individuals will get some form of cancer during their 
lifetime (http://www.cancerregistry.fi). Cancer is a genetic disorder, which means 
that mutations in specific genes offer a selective growth advantage for specific 
cells. These transformed cells then form a tumor in a specific tissue. Such 
mutations may occur sporadically or be inherited. Susceptibility to hereditary 
cancers is often inherited in an autosomal dominant manner. This means that a 
genetically predisposed individual has one mutated and one wildtype copy of a 
specific cancer-susceptibility gene in every cell. However, tumor formation 
generally begins only if the wildtype allele of this gene is also inactivated. Thus, 
tumors develop as a recessive trait and require two mutations, one germinal and 
one somatic (Knudson 1971). Typical features of inherited cancer syndromes are 
early age of onset, numerous affected family members and multiple primary 
tumors. One exceedingly common cancer in western countries is colorectal cancer 
(CRC). In Finland, it is estimated that approximately 1500 new cases of CRC will 
occur in 2004 and that approximately 5-10% of those cases are inherited 
(http://www.cancer.fi). The two most common and best defined familial forms of 
CRC are hereditary non-polyposis colorectal cancer and familial adenomatous 
polyposis (FAP) syndromes. 
Characteristics of hereditary non-polyposis colorectal cancer syndrome 
Hereditary non-polyposis colorectal cancer, also named Lynch syndrome, is the 
most common form of hereditary colon cancer accounting for 1-6% of all CRCs. 
The syndrome is characterized by the predominance of right-sided colorectal 
cancers in multiple affected generations (Lynch and de la Chapelle 2003). The 
mean age of onset is 45 years compared to 65 years in sporadic CRCs (Lynch and 
de la Chapelle 1999). In addition to CRC, HNPCC families display an excess of 
extracolonic cancers; notably carcinoma of the endometrium, ovary, stomach, 
small bovel, pancreas, hepatobiliary tract, brain and upper uroepithelial tract 
(Watson and Lynch 1994; Aarnio et al. 1999). However, the colon and 
endometrium are the two most commonly affected tissues in HNPCC and it is 
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reported that the incidence of endometrial cancer (EC) exceeds even that of CRC 
in females (Aarnio et al. 1999).  
 
The genetic basis for HNPCC became evident in the early 1990s with the 
demonstration that a germline mutation in a DNA mismatch repair gene results 
in this syndrome (Peltomäki et al. 1993). The direct consequence of defective DNA 
mismatch repair is the so-called mutator phenotype which creates genetic 
instability throughout the genome (Aaltonen et al. 1993). Susceptibility to HNPCC 
is inherited in an autosomal dominant fashion. An inherited alteration in a 
mismatch repair gene does not as such result in widespread developmental 
anomalies, because a wildtype allele provides sufficient DNA mismatch repair 
activity. Thus, before a tumor forms, the second copy of the affected DNA 
mismatch repair gene has to be somatically inactivated (Hemminki et al. 1994). 
This means that the tumor develops as a recessive trait, which requires bi-allelic 
gene inactivation (Knudson 1971). The reasons why this bi-allelic gene 
inactivation occurs more frequently in the colon and endometrium than in other 
organs are not yet understood. 
 
The first event in HNPCC-related tumorigenesis is the inactivation of a MMR 
gene (Aaltonen et al. 1994, Shibata et al. 1994; Konishi et al. 1996; Tannergård et al. 
1997, de Leeuw et al. 2000). DNA MMR deficiency then leads to the inactivation 
of many growth-regulatory genes that contain coding nucleotide repeats. Many of 
these affected genes are general tumor suppressor genes (Markowitz et al. 1995; 
Parsons et al. 1995; Souza et al. 1996; Chadwick et al. 2000; Guanti et al. 2000; Piao 
et al. 2000), as well as genes that function in DNA mismatch repair (Malkhosyan 
et al. 1996), Wnt signaling (Duval et al. 1999a; Liu et al. 2000) and apoptotic 
pathways (Rampino et al. 1997). Thus, DNA MMR deficiency promotes the 
activation of many pathways which lead to the expression of genes that favor cell 
growth. 
  
Clinically, HNPCC syndrome is not as clearly defined as for example FAP, the 
other common hereditary colon cancer syndrome, with hundreds to thousands of 
colorectal polyps (Groden et al. 1991; Nishisho et al. 1991). In HNPCC, there is no 
tendency for extensive polyposis, and hence it is not easily distinguished from 
sporadic CRC. For the uniform diagnosis of HNPCC, the first international 
criteria were defined in 1991 (Vasen et al. 1991). These so-called Amsterdam 
criteria I were later considered to be too restrictive and the new, less stringent 
Amsterdam criteria II were established in 1999. These criteria also accept, in 
 14
addition to CRC, extracolonic carcinomas, notably ECs (Table 1) (Vasen et al. 
1999). Microsatellite instability is the most characteristic feature of HNPCC-
related tumors, even if it also occurs in about 20% of sporadic counterparts of 
tumors belonging to the HNPCC tumor spectrum (Helland et al. 1997; Boland et 
al. 1998; Gurin et al. 1999; Peltomäki 2001). Thus, MSI testing is an important tool 
in identifying HNPCC patients who do not meet the Amsterdam criteria, but 
whose tumors still show the MSI phenotype. The Bethesda guidelines were 
formulated in 1997 and revised in 2004 to identify CRC patients who should be 
tested for MSI (Table 1) (Rodriguez-Bigas et al. 1997; Umar et al. 2004). MSI 
testing is also frequently used to select cancer patients for mutation analysis of 
HNPCC genes (Aaltonen et al. 1998; Wijnen et al. 1998).  
Table 1 Clinical criteria for the diagnosis of the HNPCC syndrome 
Amsterdam criteria I (Vasen et al. 1991) 
At least three relatives must have histologically verified colorectal cancer: 
One must be a first degree relative of the other two 
At least two successive generations must be affected 
At least one of the relatives with colorectal cancer must have received the diagnosis before the age 
of 50 years 
Familial adenomatous polyposis should have been excluded 
Amsterdam criteria II (Vasen et al. 1999) 
At least three relatives must have a cancer associated with HNPCC (colorectal, endometrial, stomach, ovary, 
ureter or renal pelvis, brain, small-bowel, hepatobiliary tract or skin): 
One must be a first degree relative of the other two 
At least two successive generations must be affected 
At least one of the relatives with cancer associated with HNPCC should have received the 
diagnosis before the age of 50 years 
Familial adenomatous polyposis should have been excluded in any relative with colorectal cancer 
Presence of tumor should be verified whenever possible 
Bethesda criteria (Umar et al. 2004) 
Tumors from individuals should be tested for MSI in the following situations: 
CRC diagnosed in a patient who is less than 50 years of age 
Presence of synchronous, metachronous CRC, or other HNPCC-related tumors, regardless of age  
CRC with high MSI histology diagnosed in a patient who is less than 60 years of age 
CRC diagnosed in one or more first-degree relatives with an HNPCC-related tumor, with one of 
the cancers being diagnosed under age 50 years 
CRC diagnosed in two or more first- or second-degree relatives with HNPCC-related tumors, 
regardless of age 
The table is adapted and modified from Lynch and de la Chapelle 2003 
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DNA MISMATCH REPAIR 
Overview of DNA mismatch repair 
DNA mismatch repair is one of the repair processes that are required to maintain 
genomic stability in prokaryotes and eukaryotes. The main function of MMR is to 
correct single base mismatches and insertion-deletion loops (IDLs), which arise 
during replication and escape from the proofreading activity of DNA 
polymerases. Mismatches and IDLs can also result from recombination or DNA 
damage. 
 
Cells deficient in MMR exhibit a mutator phenotype in which the spontaneous 
mutation rate is greatly elevated. This can be recognized from frameshift 
mutations in many regions throughout the genome where there are short 
tandemly arranged, identical segments of DNA. These repeating units are called 
short tandem repeats or microsatellites and they are from one to four base pairs in 
length. In addition, MMR-deficient cells can be hyper-recombinogenic because 
MMR normally prevents recombination between divergent sequences, thus 
promoting genetic stability (Sugawara et al. 1997). The subset of proteins involved 
in the MMR reaction are also implicated in other functions, such as double-strand 
break repair (Marsischky et al. 1999), meiotic and mitotic recombination (Wang et 
al. 1999a), the transcription-coupled nucleotide-excision repair pathway (Mellon 
et al. 1996; Mellon and Champe 1996), cell-cycle regulation (Davis et al. 1998) and 
the TP53-dependent apoptotic response to a variety of forms of damage to DNA. 
(Duckett et al. 1999). Thus, the MMR proteins play a critical role in many 
fundamental cellular processes. 
 
The MMR mechanism was originally identified in the bacterium Escherichia coli (E. 
coli) (Glickman et al. 1980).  The importance of this repair system in humans 
became evident with the demonstration that its inactivation is the primary cause 
of hereditary non-polyposis colorectal cancer syndrome (Aaltonen et al. 1993; 
Peltomäki et al. 1993). The key components of the MMR mechanism are conserved 
in evolution, which has been a great help in attempting to define the 
corresponding system in eukaryotes. Multiple homologs of the E. coli MMR genes 
have been found in yeast and mammals. Yeast MMR has been characterized most 
extensively in Saccharomyces cerevisiae (S. cerevisiae) (Schar et al. 1997) and 
knowledge of the human system is mainly based on studies in this organism. The 
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key MMR components have now been identified in yeast and human. However, 
many specific proteins and their major activities need still to be specified. 
DNA mismatch repair reaction 
The repair process consists of four principal steps: (1) mismatch recognition, (2) 
repairosome assembly, (3) strand discrimination linked to degradation of the 
newly synthesized strand and (4) resynthesis of excised strand. Some major 
activities and components of the DNA mismatch repair reaction in bacteria, yeast 
and humans are listed in Table 2. Figure 1 shows a putative model of the human 
MMR mechanism. 
Table 2 The proteins required for DNA mismatch repair in E. coli, S. cerevisiae and H. 
sapiens 
Activity or function E. coli S. cerevisiae H. sapiens 
Mismatch recognition MutS (ATPase) 
β-clamp 
MutSα (Msh2+Msh6) 
MutSβ (Msh2+Msh3) 
PCNA? 
MutSα (MSH2+MSH6) 
MutSβ (MSH2+MSH3) 
PCNA? 
Coupling of mismatch 
recognition to the 
subsequent steps of 
repair 
MutL (ATPase) MutLα (Mlh1+Pms1) 
MutLβ (Mlh1+Mlh3) 
MutL (Mlh1+Mlh2) 
MutLα (MLH1+PMS2) 
MutLβ (MLH1+PMS1) 
MutL (MLH1+MLH3) 
Strand discrimination MutH (GATC 
endonuclease) 
Strand discontinuity? 
PCNA? 
Strand discontinuity? 
PCNA? 
Unwinding of DNA DNA helicase II 
(uvrD/MutU) 
DNA helicase? DNA helicase? 
Excision of mismatch 
containing portion 
ExoVII or RecJ (5’-3’) 
ExoI, ExoVII  
or ExoX (3’-5’) 
ExoI (5’-3’) 
RAD27? (5’-3’) 
DNA Polymerase δ (3’-5’)
DNA Polymerase ε (3’-5’) 
 
HEXI (EXOI) (5’-3’)  
FEN1 (RAD27)? (5’-3’) 
DNA Polymerase δ (3’-5’)
DNA Polymerase ε (3’-5’) 
 
Protection of single-
stranded template 
SSB RPA RPA 
Repair synthesis DNA polymerase III DNA polymerase δ 
DNA polymerase ε? 
DNA polymerase δ 
DNA polymerase ε? 
Ligation DNA ligase DNA ligase I? DNA ligase I? 
?, remains to be identified  
Exo, exonuclease 
PCNA, proliferating cell nuclear antigen  
RPA, replication protein A  
SSB, single-strand DNA-binding protein 
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Figure 1 Putative model of the human MMR reaction. MSH2-MSH6 heterodimer (MutSα) 
recognizes the mismatched T-G pair, where the T is in the newly replicated strand. Prior 
to mismatch recognition, MSH2-MSH6 has formed a ternary complex with proliferating 
cell nuclear antigen (PCNA) and fully base-paired DNA. Once this ternary complex 
encounters the mispair, the MSH2-MSH6 is transferred from PCNA to the mispair, 
PCNA exits the complex and the MMR pathway is activated (Lau and Kolodner 2003). 
The heterodimer undergoes a conformational change driven by ATP and slides along 
DNA forming a loop (Iaccarino et al. 1998). The assembly of MLH1-PMS2 complex 
(MutLα) onto MSH2-MSH6 at the mispair couples mismatch recognition to further steps  
along the pathway(Fang and Modrich 1993; Li and Modrich 1995). Excision of a large, 
newly replicated DNA fragment containing the mismatched T is initiated by DNA 
exonuclease(s) and DNA helicase(s). DNA exonuclease cleaves nucleotides one at a time 
from the end of the polynucleotide chain and DNA helicase separates the strands of 
DNA. The method of discrimination between the template and the newly synthesized 
strand is unknown. It is possible that strand discontinuities mark the nascent strand 
during replication in vivo (Holmes et al. 1990; Thomas et al. 1991). Other model suggests 
that PCNA acts as a link between the MMR complex and DNA polymerase at the 
replication fork, possibly facilitating recognition and repair of the nascent strand (Umar 
et al. 1996). Resynthesis of the excised strand appears to be executed by DNA polymerase 
δ and possibly DNA polymerase ε (Thomas et al. 1991; Modrich 1997), PCNA and 
replication protein A (RPA) (Lin et al. 1998). The DNA ligase(s) that completes the MMR 
reaction remains to be identified. As a result of the MMR reaction, the mismatched T has 
been corrected to C, which is the normal pair of G. Other candidate proteins engaged in 
human DNA mismatch repair are listed in Table 2. 
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Main protein complexes in human DNA mismatch repair  
In human cells, the mismatch recognition occurs by two MutS homologs whose 
specificities are very similar to their yeast counterparts. MutSα, a heterodimeric 
complex of the MSH2 and MSH6 proteins, recognizes base-base mismatches and 
one basepair IDLs, whereas MutSβ, a heterodimeric complex of the MSH2 and 
MSH3 proteins, preferentially binds to 2-4 basepair IDLs (Acharya et al. 1996; 
Genschel et al. 1998). The MSH6 and MSH3 proteins are functionally redundant 
so that MSH6 can partially compensate for the function of MSH3 but not vice versa 
(Marsischky et al. 1996; Edelmann et al. 1997; Das Gupta and Kolodner 2000; 
Edelmann et al. 2000). The cellular level of the MutSα complex is much higher 
than MutSβ indicating that it has a major role in mismatch recognition 
(Drummond et al. 1997; Marra et al. 1998). After recognition, a second 
heterodimeric complex, formed by MLH1 and PMS2 (MutLα), couples mismatch 
recognition with the subsequent steps of the repair process (Fang and Modrich 
1993; Li and Modrich 1995). The specific proteins that function in strand 
discrimination, unwinding of DNA, excision of the mismatch containing portion, 
repair synthesis and ligation are not yet known (Table 2, Figure 1). 
 
The three above-mentioned heterodimers, MutSα, MutSβ and MutLα, are of a 
particular interest in the human MMR reaction. It has been hypothesized that 
because the MSH3 and MSH6 functions are partially redundant, inactivation of 
either gene leads to only a weak mutator phenotype. Accordingly, the cells 
deficient in both MSH3 and MSH6 proteins have a high mutation rate, similar to 
that observed in the MSH2-deficient cells (de Wind et al. 1999). MSH6-deficiency 
typically causes single base substitutions, MSH3-deficiency causes gains or losses 
of short repeat units, whereas MSH2-deficiency causes both single substitutions 
and gains and losses. MLH1 can form a heterodimeric complex with PMS1, PMS2 
or MLH3. Of those, MLH1-PMS2 is a major component of MMR (Kondo et al. 
2001). MLH1-MLH3 has been shown to participate in the repair of IDLs with 
MutSβ in yeast but its role in human MMR, as well as the role of the MLH1-PMS1 
complex, still remains putative (Lipkin et al. 2000). MLH1 is, however, a common 
subunit to all MutL complexes and its deficiency leads to a severe mutator 
phenotype similar to MSH2 deficiency. Interestingly, only the MSH2 and MLH1 
proteins are stable as monomers, while the other proteins, MSH6, MSH3 and 
PMS2, are unstable in the absence of their partners. Thus, the MSH2-deficient cells 
also show reduced levels of MSH3 and MSH6 (Marra et al. 1998; de Wind et al. 
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1999; Chang et al. 2000) and, in the absence of MLH1, PMS2 is vulnerable to 
degradation (Räschle et al. 1999). 
MMR genes and predisposition to HNPCC syndrome 
Germline mutations in MMR genes 
Germline mutations in four different MMR genes, MSH2, MLH1, MSH6 and 
PMS2, are convincingly associated with HNPCC. Three further genes, MLH3, 
PMS1 and MSH3, have also been implicated in predisposition to HNPCC, but 
their roles are less clear (Peltomäki and Vasen 2004). The previous International 
Collaborative Group (ICG) on HNPCC, the current International Society for 
Gastrointestinal Hereditary Tumors (InSiGHT), maintains a database of 
syndrome-associated pathogenic mutations and polymorphisms 
(http://www.nfdht.nl). The database was established in 1994, and nowadays it 
contains information on more than 450 different MMR gene alterations that occur 
in 750 families from different parts of the world (Peltomäki et al. 1997; Peltomäki 
and Vasen 2004). Two genes, MLH1 and MSH2, account for 90% of all mutations. 
The third most common susceptibility gene, MSH6, accounts for 7% of all 
mutations and the remaining MMR genes for less than 5% (Table 3). 
Table 3 Number of germline mutations in different MMR genes (http://www.nfdht.nl)  
MMR 
gene 
Chromosomal 
location 
Number of germline mutations (% of total) 
in 1996                  in 2004 
MLH1 3p21-23 75(60%) 241 (53%) 
MSH2 2p21 48 (38%) 169 (37%) 
MSH6 2p21 0(0%) 32 (7%) 
MLH3 14q24.3 0(0%) 10 (2%) 
PMS2 7p22 2(2%) 5 (1%) 
PMS1 2q31-33 1(1%) 1 (0,2%) 
Total  126 (101%) 458 (100,2%) 
Mutations in MMR genes are scattered throughout the coding sequence. 
Frameshift and nonsense mutations that lead to truncated proteins are a common 
type of germline mutation in the MLH1, MSH2 and MSH6 genes. Also a great 
proportion of the alterations, especially in the MSH6 and MLH3 genes, consist of 
missense change that cause a single amino acid substitution (Figure 2) (Peltomäki 
and Vasen 2004; http://www.nfdht.nl). Truncating mutations that are present in 
large HNPCC families are usually considered pathogenic changes. However, an 
increasing proportion of mutations listed in the database are of the missense type 
that occurs in small and atypical HNPCC families (Peltomäki and Vasen 2004). 
Those mutations and their pathogenicity pose important questions to both 
clinicians and researches. 
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Figure 2 Types of germline mutations in HNPCC-associated MMR genes (Peltomäki and 
Vasen 2004) 
Two mismatch repair gene mutations in the same patient 
Rarely, a patient can carry two mutations either in a single MMR gene or in two 
separate MMR genes. The patients who carry homozygous mutations in both 
alleles of MLH1 or MSH2 have been shown to express an atypical tumor spectrum 
with hematological malignancy and neurofibromatosis type 1 (NF-1), suggesting 
that development of hematological malignancies and NF-1 are also a consequence 
of the mutator phenotype caused by MMR deficiency (Ricciardone et al. 1999; 
Wang et al. 1999b; Vilkki et al. 2001; Whiteside et al. 2002; Raevaara et al. 2004). 
The few reports from patients who carry a compound heterozygous mutation in 
MLH1 or PMS2 demonstrate that in these cases, tumors (breast, brain, colon) 
display the MSI phenotype, but the risk for colorectal cancer seems to be no 
greater than in heterozygous mutation carriers (Hackman et al. 1997; De Rosa et 
al. 2000). Neither do patients who have inherited two mutations in different MMR 
genes display a clinically more severe phenotype than heterozygous mutation 
carriers in general (Wu et al. 1999, 2001; Samowitz et al. 2001).  
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MLH1 and MSH2 mutations are associated with classical HNPCC families 
Germline mutations in MLH1 and MSH2 are mainly associated with classical 
HNPCC families that fulfill the Amsterdam criteria I (Table 1) and display a high 
MSI phenotype in tumor cells (Liu et al. 1996, Nyström-Lahti et al. 1996). A high 
degree of MSI is defined as instability at > 2/5 or > 30-40% of studied microsatellite 
loci (Boland et al. 1998). Both MLH1 and MSH2 encode protein products that are 
essential in the mismatch repair reaction and indispensable subunits of the 
heterodimeric complexes (Figure 1, Table 2), which explains the severe 
consequences of mutations in these genes. 
MSH6 mutations are associated with putative HNPCC families 
The role of the MSH6 gene in HNPCC predisposition is not so obvious. MSH6 
mutations are rarely found in HNPCC kindreds that fulfill the original 
Amsterdam criteria I (Akiyama et al. 1997; Miyaki et al. 1997; Goodfellow et al. 
2003) or even the revised, less stringent criteria (Table 1) (Wijnen et al. 1999; Wu et 
al. 1999; Plaschke et al. 2004), but are identified mostly in families with putative or 
atypical HNPCC (Kolodner et al. 1999; Verma et al. 1999).  
 
Germline MSH6 mutations appear to be associated with a later age of cancer onset 
than MLH1 or MSH2 mutations. The mean age at diagnosis is 55 years, which is 
approximately ten years later than in MLH1 or MSH2 mutation carriers, but still 
significantly less than in sporadic cases (Miyaki et al. 1997; Wijnen et al. 1999; de 
Leeuw et al. 2000; Wagner et al. 2001; Goodfellow et al. 2003; Cederquist et al. 
2004). Patients with MSH6 mutations remarkably often display endometrial 
cancer or atypical endometrial hyperplasia, the precursor of endometrial 
carcinoma (Miyaki et al. 1997; Wijnen et al. 1999; Wagner et al. 2001; Berends et al. 
2002; Cederquist et al. 2004). The significance of MSH6 in the development of EC 
is emphasized by the observation that lack of MSH6 protein characterizes ECs but 
not CRCs in HNPCC patients carrying the MLH1 mutation (Schweizer et al. 2001).  
 
A substantial proportion of MSH6-deficient colorectal and endometrial cancers 
show a lack of or only a low degree of MSI (Wu et al. 1999; Plaschke et al. 2000; 
Wagner et al. 2001). Because of the redundant function of MSH6 and MSH3 
proteins, MSH6 deficiency mainly causes base substitutions (Marsischky et al. 
1996; Sia et al. 1997) and instability in mononucleotide repeats (Akiyama et al. 
1997; Miyaki et al. 1997; Verma et al. 1999; de Leeuw et al. 2000; Plaschke et al. 
2000, 2004; Cederquist et al. 2004). However, it has also been reported that, in 
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MSH6-deficient cells, instability in dinucleotide repetitive regions is as frequent as 
that of mononucleotide repeats (Berends et al. 2002).  
 
THE PATHOGENICITY OF INHERITED MMR GENE MUTATIONS 
The question of the pathogenicity of a sequence alteration  
Inherited mutations in mismatch repair genes are distributed throughout the 
coding sequence and most mutations are unique (Peltomäki et al. 1997; Peltomäki 
and Vasen 2004; http://www.nfdht.nl). This means that usually the entire genes 
need to be screened for the detection of a predisposing mutation in a new family. 
A sequence alteration that results in a truncated protein is considered pathogenic, 
because it typically causes the loss of important functional domains. Furthermore, 
it generally leads to the absence of any detectable gene product in tumor tissue, 
which supports the assumption that the mutation is pathogenic. Although all 
alterations in the genome are potentially deleterious changes, the pathogenic 
significance of missense mutations is often difficult to determine. They do not 
necessarily affect the expression or stability of the protein, which can result in 
positive immunohistochemical staining in the tumor even though the function of 
the protein may be defective.  
 
A significant proportion of all mutations identified in MLH1, MSH2 and MSH6 
are of the missense type (Figure 2). Particularly, interpreting the pathogenicity of 
missense alterations, which are linked to small and putative HNPCC families 
lacking the typical clinical and molecular features of the syndrome, is very 
difficult (Kolodner et al. 1999; Wijnen et al. 1999; Wu et al. 1999; Parc et al. 2000; 
Wagner et al. 2001). It can also be impossible to interpret the significance of 
missense alteration found in patients who carry two different MMR gene 
mutations. It is often far from clear which one of the identified mutations is 
pathogenic, or if both of them are needed to cause MMR deficiency and cancer 
susceptibility (Wu et al. 1999, 2001; Samowitz et al. 2001).  
 
It is most important for clinicians and genetic counsellors that pathogenic 
alterations can be distinguished from nonpathogenic variants, since counseling 
must be based on a reliable assessment of the pathogenicity of the mutation. The 
optimal approach to evaluate the pathogenicity of a nontruncating mutation is to 
clarify whether the detected mutation and the disease cosegregate in a family. 
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Unfortunately, segregation studies are often hindered by an insufficient family 
size or the unavailability of clinical specimens.  
 
Many reports classify missense mutations as most likely to be pathogenic if they 
fulfill the following criteria: (1) the mutated codon is located in an evolutionarily 
conserved residue; (2) the amino acid substitution is significant, for example it 
causes a change in polarity; (3) the mutation is not present in healthy control 
individuals; (4) other MMR germline mutations are excluded in the kindred and 
(5) the mutation segregates with the disease phenotype (Kolodner et al. 1999; Wu 
et al. 1999; Trojan et al. 2002). In addition to these criteria, the location of the 
mutated codon in a critical functional domain may be relevant for protein activity. 
In many cases, these criteria are not fulfilled but the mutation is still listed as 
pathogenic rather than as a polymorphism in the HNPCC mutation database 
(http://www.nfdht.nl). Determining a missense mutation found in an HNPCC 
family as pathogenic is often difficult without additional confirmatory studies. 
Thus biochemical characterization and functional analyses of the mutated MMR 
proteins are necessary.   
 
Functional tests to determine the pathogenicity of MMR gene mutations 
In vitro and in vivo MMR protein expression assays 
A decreased in the amount of mutated MMR protein compared to wildtype 
protein might be an indication of the mutation’s pathogenicity (Brieger et al. 2002; 
Nyström-Lahti et al. 2002; Raevaara et al. 2002; Trojan et al. 2002). Several groups 
have used different expression systems to produce mutated MSH2 and MLH1 
proteins (Palombo et al. 1996; Iaccarino et al. 1998; Marra et al. 1998; Brieger et al. 
2002; Nyström-Lahti et al. 2002; Räschle et al. 2002; Trojan et al. 2002; Raevaara et 
al. 2003). For protein production, the target cells are cotransfected with MSH2 and 
MSH6 or MLH1 and PMS2 expression vectors, to produce heterodimeric 
complexes of MutSα and MutLα, respectively, since both MSH6 and PMS2 are 
unstable in the absence of their partner proteins (Marra et al. 1998; de Wind et al. 
1999; Räschle et al. 1999; Chang et al. 2000). 
 
The Baculovirus expression system is one of the most widely used expression 
systems to produce human MMR proteins in cultured insect cells (Palombo et al. 
1996; Iaccarino et al. 1998; Marra et al. 1998; Nyström-Lahti et al. 2002; Räschle et 
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al. 2002). This expression system is based on recombinant baculovirus constructs, 
in which the heterologous gene is placed under the transcriptional control of the 
strong polyhedrin promoter and abundantly expressed during transient 
transfection. The produced proteins are processed, modified and targeted to their 
appropriate cellular locations, where they are functionally similar to their 
authentic counterparts (Bac-to-Bac baculovirus expression system, Instruction 
Manual, 2003).  
 
The human homologous expression system has been used to study the 
biochemical properties of MSH2 and MLH1 protein variants (Brieger et al. 2002; 
Trojan et al. 2002, Raevaara et al. 2003). In these studies, mismatch repair-deficient 
cell lines, LoVo (MSH2-/-), HCT 116 (MLH1-/-) or the human embryonic kidney 
fibroblast cell line 293T (MLH1-/-), are transiently transfected with different 
expression vector constructs to study the expression and stability of mutated 
MSH2 or MLH1, respectively. Here, the amount of some MSH2 and MLH1 
variants has been shown to decrease compared to wildtype protein levels, 
suggesting that mutant proteins or mutant mRNAs are less stable than the 
corresponding wildtype molecules (Brieger et al. 2002; Trojan et al. 2002; Raevaara 
et al. 2003).  
 
The Baculovirus expression system is a very efficient method for producing high 
amounts of protein, and intracellular proteins in particular, when compared to 
other eukaryotic expression systems (Luckow et al. 1993). Production of the 
mutated MMR proteins in vivo in the human expression system is not as efficient 
as in the baculovirus system (Trojan et al. 2002; Raevaara et al. 2003). Since 
functional assays generally require more recombinant protein than can be 
produced in vivo, the Baculovirus expression system is widely used. Moreover, 
the human expression system always requires a suitable cell line, which is 
deficient for the MMR gene of interest, in order to produce that mismatch repair 
protein, and hence it is not appropriate for all MMR genes.  
In vitro interaction assays 
Guerrette et al. (1998, 1999) have used a glutathione S-transferase (GST) fusion 
protein interaction assay to evaluate the effects of MLH1 and MSH2 missense 
alterations on protein interactions. In the assay, the recombinant GST fusion 
protein is incubated with 35S-labeled cell lysate in the presence of glutathione-
agarose beads. The proteins are allowed to associate, and are then fractionated by 
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polyacrylamide gel electrophoresis and subjected to autoradiography. It was 
shown that both MSH2-MSH6 and MSH2-MSH3 heterodimers have two distinct 
interaction regions (Guerrette et al. 1998), while the interaction between the two 
components of the MLH1-PMS2 heterodimer is located in one region, in the 
carboxyl terminus of both proteins (Guerrette et al. 1999). Several MSH2 missense 
alterations found in HNPCC patients and located in the consensus interaction 
regions showed no defect in the MSH6-MSH2 or MSH3-MSH2 interactions, 
whereas deficiencies in the interaction of MLH1 with PMS2 was shown to be 
associated with HNPCC (Guerrette et al. 1998,1999). 
  
Coimmunoprecipitation assays provide a different method to study the effect of a 
MMR missense mutation on protein-protein interactions (Brieger et al. 2002; 
Nyström-Lahti et al. 2002). A protein of interest is specifically 
immunoprecipitated from the cell extracts using a specific antibody and the 
immunoprecipitates are then resolved on an polyacrylamide gel and detected by 
western blotting with antibodies directed against the protein of interest and its 
associated proteins.  
 
In the glutathione S-transferase fusion protein interaction assay, the amino-
terminal GST fusion of the MMR protein construct may change the native folding 
of the protein and thus affect its interactions. Furthermore, this in vitro assay is not 
quantitative and cannot determine the effects of an altered interaction on the 
MMR process in vivo. The major advantage of the coimmunoprecipitation assay 
compared to GST fusion assay is that it allows studying the proteins in their 
native conformation. However, it may not be sensitive enough to detect weak 
interactions between proteins (Guerrette et al. 1998). It also requires an 
appropriate antibody for coimmunoprecipitation. So far, none of the commercial 
anti-MSH2-antibodies are effective enough to coimmunoprecipitate MSH2 
together with MSH6 protein (Acharya et al. 1996; Brieger et al. 2002), whereas this 
interaction can be shown with monoclonal anti-MSH6-antibody (Matton et al. 
2000).  
In vivo bacterial- and yeast-based functional assays    
Quaresima et al. (2003) have described a simple method to test the effect of 
overexpressed wildtype or mutated human MLH1 protein upon the mismatch 
repair mechanism in E. coli.  This assay is based on the presumption that human 
MLH1 protein is able to interact with bacterial MutL and MutS proteins in vivo. In 
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the assay, the E. coli strain, which carries a lac +1 frameshift mutation (CCC to 
CCCC), is transfected with a plasmid expressing wildtype or mutated human 
MLH1 protein. The Lac+ reversion rate is used as an indication of functionality of 
the tested protein (Longerich et al. 1995). The wildtype human MLH1 as well as 
functional MLH1 variants display the mutator phenotype due to their ability to 
interact with MutL and MutS, whereas pathogenic variants show weaker 
interaction with bacterial MMR proteins and have no effect on the Lac+ reversion 
rate (Quaresima et al. 2003). 
 
Shimodaira et al. (1998) have described a yeast-based functional assay to test 
human MLH1 mutations. This assay is based on the assumption that the function 
of human MLH1 can be monitored in S. cerevisiae, because the MMR function is 
conserved between these species. In the assay, human wildtype or mutated MLH1 
cDNA is overexpressed in a MMR-proficient yeast strain. A defective MMR 
protein causes an increase in the mutation rate of the canavanine resistance 
(CAN1) gene, and in the reversion of the hom3-10 allele in yeast. Highly expressed 
wildtype human MLH1 increases the rate of accumulation of CAN1 mutations 
and Hom+ reversions and thus causes the dominant mutator phenotype. The 
mutations in human MLH1 which prevent the proper protein function totally or 
partially inactivate this dominant mutator effect. The assay is thus based on 
interference of functional human MLH1 protein, which competes with native 
yeast MLH1 protein and results in only partial MMR activity.  
 
Shcherbakova and Kunkel (1999) have used a different kind of yeast-based assay 
to examine the functional consequences of human MLH1 missense mutations. 
They showed that overexpression of yeast MLH1 in a wildtype yeast strain 
increases the mutation rate, possibly by sequestering and preventing other 
proteins from participating in the MMR reaction. Here, human MLH1 mutations 
are introduced into the homologous sequence in yeast MLH1 and stay pathogenic 
if the mutation results in a strong mutator phenotype.  
 
Ellison et al. (2001) have evaluated the effect of missense alterations in MLH1 
function by using a reporter gene which measures the stability of an in-frame 
(GT)16 tract in S. cerevisiae.  Besides introducing the missense changes at the 
homologous yeast codon, a hybrid human-yeast MLH1 protein was constructed. 
The hybrid proteins were shown to be functional in MMR in vivo. 
 
 27
Kolodner et al. (1999) have also described a yeast-based assay but in distinction 
from the other assays, which are used to test MLH1 mutations, this was 
developed for the testing of MSH6 missense mutations. Here, the mutations are 
introduced into the S. cerevisiae MSH6 gene; the mutated plasmids are 
transformed into a MMR-deficient msh3 msh6 double mutant strain and the rate of 
reversion of the hom3-10 frameshift mutation is determined by fluctuation 
analysis (Marsischky et al. 1996). The amino acid substitution is classified as a loss 
of function mutation if the mutated plasmid fails to complement the MMR-
deficient phenotype. The wildtype MSH6 plasmid is able to fully complement this 
defect. 
 
All of the bacterial- and yeast-based functional tests rely on the expression of a 
particular phenotype in a heterologous system. Quaresima’s and Shimodaira’s 
assays assume that the function of a human MMR protein can be monitored in 
different organisms (Shimodaira et al. 1998; Quaresima et al. 2003). 
Shcherbakova’s and Kolodner’s assays require that affected amino acid residues 
are evolutionarily conserved and assume that homologous mutations in S. 
cerevisiae give the same phenotype in yeast as the original mutations in human 
cells (Kolodner et al. 1999; Shcherbakova and Kunkel 1999). Ellison’s test has 
overcome the limitation of studying only evolutionarily conserved codons by 
constructing human-yeast hybrid proteins (Ellison et al. 2001). All of these assays 
are quantitative, since the result is based on the rate of reversion of frameshift 
mutations. They are also facile and less time-consuming than in vitro functional 
assays. 
In vitro MMR assays  
Nyström-Lahti et al. (2002) have adapted and used the human cell-based in vitro 
mismatch repair assay (Lahue et al. 1989; Holmes et al. 1990) to study the effect of 
MLH1 mutations in the MMR reaction. In this assay, the total protein extract of 
baculovirus-infected insect cells, which contains overexpressed recombinant 
human MLH1, is incubated together with nuclear extract from the mismatch 
repair-deficient cell line HCT116, which lacks functional MLH1. The repair 
reaction is carried out in vitro using a nicked circular heteroduplex molecule, 
which contains a G•T mismatch, as the substrate (Lu et al. 1983; Lahue et al. 1989; 
Holmes et al. 1990). If HCT116 nuclear extract complemented with MLH1 variant 
can correct the mismatch, a specific restriction enzyme is able to cut the 
heteroduplex, and the repair efficiency can be measured by the cleavage 
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efficiency. MMR-proficient nuclear extract and MLH1-deficient nuclear extract 
complemented with wildtype MLH1 are used as positive controls in the assay. 
MLH1-deficient nuclear extract is used as a negative control.   
 
Trojan et al. (2002) have described a modified version of the in vitro MMR assay. 
The repair reaction uses a bacteriophage heteroduplex containing a G•T mismatch 
in the coding sequence of the lacZ α-complementation gene fragment as the 
substrate, and cytoplasmic extract from MLH1-deficient cell line is complemented 
with recombinant human MLH1 expressed in insect cells. The purified DNA is 
introduced into the E. coli strain by electroporation and plated along with the α-
complementation strain. If no repair occurs, a high percentage of mixed plaques, 
containing both blue and colorless progeny, are observed. A reduction in the 
percentage of mixed plaques and the concomitant increase in single-color plaques 
are indicative of repair (Thomas et al. 1991; Marra et al. 1998).     
 
The in vitro MMR assays allow studying the functionality of the mutated proteins 
in a homologous human system. Their advantages compared to bacterial-based, 
yeast-based and interaction assays are that here it is possible to study the protein-
protein interaction of any two known components of the human MMR system. 
Furthermore, all in-frame mutations from missense mutations to small exonical 
insertions/deletions, irrespective of their evolutionary conservation status or 
location in a gene, can be investigated (Nyström-Lahti et al. 2002; Raevaara et al. 
2002; Trojan et al. 2002).  
TUMORIGENESIS IN HNPCC 
DNA MMR deficiency as the first step in tumorigenesis 
The predisposition to HNPCC is inherited in an autosomal dominant fashion. 
According to Alfred Knudson’s two hit hypothesis, tumor formation requires two 
hits (one germinal and one somatic) in a MMR gene (Knudson 1971; Hemminki et 
al. 1994). The direct consequence of defective DNA mismatch repair is the 
mutator phenotype characterized by high microsatellite instability in tumor tissue 
(Ionov et al. 1993; Thibodeau et al. 1993). Mutation rates in MMR-deficient cells 
are 100 - 1000-fold higher as compared with normal cells (Parsons et al. 1993; 
Bhattacharyya et al. 1994). Sporadic counterparts of carcinomas included in the 
HNPCC tumor spectrum can also show a high degree of MSI, and approximately 
15% of sporadic colon and 25% of sporadic endometrium carcinomas display the 
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mutator phenotype (Helland et al. 1997; Boland et al. 1998; Gurin et al. 1999). The 
majority of sporadic MMR-deficient tumors are due to bi-allelic silencing of the 
MLH1 gene, which mostly results from promoter hypermethylation and more 
rarely from somatic mutations or loss of heterozygosity (LOH) (Liu et al. 1995; 
Kane et al. 1997; Veigl et al. 1998; Esteller et al. 1999; Kuismanen et al. 2000). 
 
Most microsatellite repeats in the genome are located within noncoding or 
intronic sequences and are thus considered to be silent. However, many genes 
also contain microsatellites within their coding regions and these microsatellite 
repeats are observed to be mutated in MSI carcinomas. Several of these mutated 
genes are well-known tumor suppressor genes, which require two genetic events 
(one in each allele) for their inactivation. In HNPCC-related tumors, the 
inactivation of MMR genes is an early event in tumorigenesis (Aaltonen et al. 
1994, Shibata et al. 1994; Konishi et al. 1996; Tannergård et al. 1997, de Leeuw et 
al. 2000). This causes the activation of the mutator pathway leading to a cascade of 
accumulating frameshift mutations in many growth-regulatory genes with coding 
microsatellites, promoting genome-wide genetic instability. 
 
Mutational and immunohistochemical analyses of target genes have been 
performed mainly in the colon and endometrium, the two most commonly 
affected tissues in HNPCC (Aarnio et al. 1999). The majority of the investigated 
tumors derived from HNPCC patients with a predisposing MSH2 or MLH1 
mutation (de Leeuw et al. 2000; Schweizer et al. 2001; Kuismanen et al. 2002). 
Because the genetic basis of organ selection in HNPCC is poorly understood, the 
comparative studies of affected target genes in HNPCC-related endometrial 
cancers (HNPCC-ECs) and colorectal cancers (HNPCC-CRCs) with an identical 
genetic predisposition have supplied unique data about tumor progression in 
these two organs (Schweizer et al. 2001; Kuismanen et al. 2002). 
 
Kuismanen et al. (2002) have shown that the target gene pattern is more 
heterogenous and involves a lower proportion of unstable markers per tumor in 
HNPCC-ECs than HNPCC-CRCs despite the same predisposing MMR mutation 
in the patients. Some target genes, such as insulin-like growth factor II receptor 
(IGFIIR) and the MMR genes MSH3 and MSH6, which contain coding 
mononucleotide repeats, seem to be fairly evenly involved in these tumors (de 
Leeuw et al. 2000; Kuismanen et al. 2002), whereas some others show considerable 
tissue specificity. For example, transforming growth factor β receptor II (TGFβRII) is 
the most frequently targeted tumor suppressor gene in colorectal cancer, but this 
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is not as common in ECs (Konishi et al. 1996; Tannergård et al. 1997; Kuismanen 
et al. 2002; Paoloni-Giacobino et al. 2002). Its alterations affect growth inhibition, 
cell death and differentiation in intestinal epithelial cells (Wu et al. 1992; 
Markowitz and Roberts 1996). The most common target gene for endometrial 
cancer seems to be PTEN (Kuismanen et al. 2002; Zhou et al. 2002), a phosphatase 
which signals through the phospoinositol-3-kinase/Akt pathway and mediates 
cell cycle arrest and cell death (Li et al 1998; Stambolic et al. 1998; Weng et al. 
1999). The considerable differences between affected target genes and their 
inactivation frequencies support the suggestion that tumor progression occurs via 
distinct mechanisms in these two organs (de Leeuw et al. 2000; Schweizer et al. 
2001; Kuismanen et al. 2002).  
General adenoma-carcinoma sequence in colon cancer formation 
The general model of colon cancer development from a pre-existing benign tumor 
to a malignant form is one of the best characterized models of tumor progression. 
Colon cancer formation is a multistep process resulting from a number of specific 
mutational events in many different genes which are members of pathways that 
control cell growth and death. Colon cancer is most commonly initiated by 
alterations in the signaling elements of the Wnt signaling pathway (Iwamoto et al. 
2000; Hao et al. 2002). It then progresses as a result of the accumulation of 
sequential events that either inactivate tumor suppressor genes or activate 
oncogenes, which require only one genetic event for their activation (Sparks et al. 
1998). The adenomatous polyposis coli (APC) gene is one of the key components in 
the Wnt signaling pathway and alterations in APC result in overactivation of this 
pathway (Morin et al. 1997).  
 
Mutational inactivation of the APC gene appears to initiate about 70% of sporadic 
colon adenocarcinomas (Miyaki et al. 1994). Germline mutations in APC 
predispose to familial adenomatous polyposis syndrome displaying numerous 
colorectal and small intestinal tumors (Groden et al. 1991; Nishisho et al. 1991). 
Mutations in APC have been detected in the smallest adenomas studied, 
indicating its very early role in colon tumorigenesis (Powell et al. 1992; Ichii et al. 
1993; Levy et al. 1994). In sporadic cases, over 90% of APC mutations result in a 
premature stop codon and truncated gene product (Miyoshi et al. 1992; Powell et 
al. 1993). 
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The other alterations that have been convincingly shown to promote colon 
carcinogenesis affect K-ras, genes on chromosome 18q, and TP53. K-ras is an 
oncogene and has been shown to be activated in about 40% of sporadic colon 
tumors. In activated form it promotes cell proliferation and mediates adenoma 
growth (Bos et al. 1987; Arber et al. 2000). LOH on 18q occurs in approximately 
70% of all colon cancers. This deleted region contains a number of tumor 
suppressor genes, for example deleted in colorectal cancer (DCC), SMAD2 and 
SMAD4, which have been shown to play a significant role in tumor progression 
from intermediate adenoma to late-stage adenoma (Vogelstein et al. 1988; Fearon 
et al. 1990; Takagi et al. 1996). TP53 is the best-studied tumor suppressor gene, 
whose function is affected in about 50% of all human tumors (Soussi et al. 2000). 
TP53 encodes a nuclear transcription factor that is involved in maintaining 
genomic stability by controlling cell cycle arrest and apoptosis, in response to 
various intra- and extracellular stress signals (Kastan et al. 1991; Yonish-Rouach et 
al. 1991; Kuerbitz et al. 1992). Mutations in TP53 occur as a late event in colon 
tumorigenesis and can be found in 50-60% of sporadic colorectal carcinomas 
(Soussi et al. 2000). Furthermore, a variety of genetic alterations have been 
described in advanced carcinoma and an unknown number of mutational steps 
are further needed for the metastatic stage. 
Wnt signaling pathway 
The function of the Wnt pathway was originally described during embryogenesis. 
The Wnt genes (homologous to wingless in Drosophila) encode secreted 
glycoprotein factors that regulate cell growth. Wnt signaling molecules bind to 
transmembrane receptors called Frizzleds and activate the pathway by a so far 
largely unknown mechanism, leading to stabilization of the protein β-catenin, 
which upregulates the expression of many target genes that favor cell growth. In 
recent years, the Wnt signaling pathway has received considerable attention 
because its overactivation has been demonstrated to play an important role in the 
formation of certain tumors, especially colorectal cancer. Although mutation or 
misexpression in Wnt genes has not directly been associated with tumorigenesis, 
mutations in many components of this pathway have been shown to be critical in 
many forms of cancer (Miller 2001; Lustig and Behrens 2003). 
  
The main components of the Wnt signaling pathway are β-catenin, APC, AXIN2 
and glycogen synthase kinase -3β (GSK-3β), which form a macromolecular 
complex in the cytoplasm. In the absence of Wnt signal molecules (Wnts), this 
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macromolecular complex directs β-catenin toward proteosomal degradation 
(Rubinfeld et al. 1996; Aberle et al. 1997; Kishida et al. 1998), thus keeping the 
cytoplasmic concentration of free β-catenin in normal cells very low. The presence 
of Wnts or mutations in APC, β-catenin (CTNNB1) or AXIN2 cause activation of 
this signaling pathway resulting in the stabilization of β-catenin (Morin et al. 
1997; Liu et al. 2000), which enters into the nucleus and associates with 
transcription factors leading to the overexpression of Wnt target genes (Figure 3). 
In general, only one of these genes is mutated in a given tumor tissue, reflecting 
their role in a common pathway (Miyaki et al. 1999; Akiyama et al. 2000; Liu et al. 
2000). 
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Figure 3 Overview of the Wnt signaling pathway. In the absence of Wnt signal molecules 
(-Wnt), APC interacts with β-catenin and they together form a macromolecular complex 
with AXIN2 and GSK-3β. In this complex, as a result of phosphorylation by GSK-3β, β-
catenin is consequently directed toward ubiquitin(Ub)-mediated proteosomal 
degradation (Rubinfeld et al. 1996; Aberle et al. 1997; Kishida et al. 1998). Thus, the 
cytoplasmic concentration of free β-catenin is very low in normal cells. Binding of Wnts 
to Frizzled receptors activates Dishevelled, which blocks the function of the 
macromolecular complex. Therefore, in the presence of Wnts (+Wnt) or after mutations in 
APC, β-catenin or AXIN2, formation of the macromolecular complex is prevented. As a 
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result, the amount of β-catenin protein increases in the cytoplasm with subsequent 
nuclear translocation and accumulation (Morin et al. 1997; Liu et al. 2000). In the nucleus, 
activated β-catenin can interact with transcription factors like T cell factor/Lymphoid 
enhancer factor (TCF/Lef) (Behrens et al. 1996; Korinek et al. 1997), leading to 
overexpression of several target genes that have been shown to promote tumor 
formation. TCF4 is the predominant TCF family member expressed in the colonic 
epithelium (Korinek et al. 1997), and it upregulates growth-regulatory genes such as C-
MYC and CYCLIN D1 (He et al. 1998; Mann et al. 1999; Tetsu and McCormick 1999). 
Consequently, mutations in Wnt signaling components have an essential role in tumor 
development. 
Tumor progression in HNPCC-related colorectal cancer 
The genetic alterations from adenoma to carcinoma stage in HNPCC-related colon 
tumors with the microsatellite mutator phenotype are quite different from that of 
sporadic microsatellite stable (MSS) colon tumors (see above), even if they do 
share several genetic alterations (Figure 4) (Yamamoto et al. 1998). However, in 
both sporadic and HNPCC-related microsatellite instable colon cancers, the 
inactivation of MMR genes is an early event in tumorigenesis (Aaltonen et al. 
1994, Shibata et al. 1994; Konishi et al. 1996; Tannergård et al. 1997).  
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Figure 4 Putative model of genetic changes associated with HNPCC-related colorectal 
cancer tumorigenesis. The most obvious difference between sporadic and HNPCC-
related colon tumorigenesis is that HNPCC-tumors are mismatch repair-defective and 
progress via the microsatellite mutator pathway.  Inactivation of a MMR gene is an early 
event in tumorigenesis. DNA mismatch repair deficiency leads to inactivation of many 
growth-regulatory genes that contain coding mononucleotide repeats. Many of these 
affected genes are general tumor suppressor genes, namely TGFβRII (Markowitz et al. 
1995; Parsons et al. 1995), IGFIIR (Souza et al. 1996), PTEN (Guanti et al. 2000), 
retinoblastoma protein-interacting zinc finger (RIZ) (Chadwick et al. 2000; Piao et al. 2000), as 
well as genes that function in DNA mismatch repair (Malkhosyan et al. 1996), Wnt 
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signaling (Duval et al. 1999a; Liu et al. 2000) and apoptotic pathways (Rampino et al. 
1997). Inactivation of the APC gene results in overactivation of the Wnt signaling 
pathway, which leads to the expression of genes that favor cell growth. Mutations in APC 
are less frequent in HNPCC-CRCs than in sporadic tumors (Konishi et al. 1996; Akiyama 
et al. 2000). However, other genes (AXIN2, TCF4) of this pathway are reported to mutate 
due to MMR deficiency and thus alter the Wnt signaling pathway and contribute to the 
development of colon cancer (Duval et al. 1999a; Liu et al. 2000). During progression 
through the adenoma-carcinoma sequence, additional alterations accumulate in 
oncogenes including K-ras (Aaltonen et al. 1993; Tannergård et al. 1997; Fujiwara et al. 
1998) and in tumor suppressor genes on chromosome 18q (DCC, Smad2, or Smad4) and 
TP53 (Lynch and de la Chapelle 2003). Target gene mutations due to MMR deficiency 
appear to occur throughout the adenoma-carcinoma sequence. The timing of many of 
these events during tumor formation remains to be mapped, but preliminary studies 
have shown that they occur at distinct phases of tumor progression. This figure is 
modified from Lynch and de la Chapelle 2003. 
In HNPCC-related CRC, TGFβRII is the most frequently targeted tumor 
suppressor gene with coding microsatellites (Konishi et al. 1996; Tannergård et al. 
1997; Kuismanen et al. 2002; Paoloni-Giacobino et al. 2002). The BAX gene is 
mutated in 30% of HNPCC-CRCs (Kuismanen et al. 2002, Paoloni-Giacobino et al. 
2002). It is a member of the Bcl-2 gene family, which promotes apoptosis via the 
TP53-regulated pathway (Oltvai et al. 1993). Mutations in the tumor suppressor 
gene TP53 are not so frequent in HNPCC-related colorectal cancers as in their 
sporadic counterparts, and it has been speculated that BAX may replace the role 
of mutant TP53 in tumorigenesis of HNPCC-CRCs (Konishi et al. 1996; Eshleman 
et al. 1998). The frequency of K-ras mutations in HNPCC-CRCs is similar to that in 
MSS CRCs (Aaltonen et al. 1993; Tannergård et al. 1997; Fujiwara et al. 1998). 
 
Alterations of the Wnt signaling pathway can be observed irrespective of the MSI 
status, indicating its general role in CRC development. The pathway has been 
shown to be overactivated in 65% of colorectal cancers related to HNPCC 
syndrome (Miyaki et al. 1999). Activating β-catenin mutations occur in about 40% 
of these tumors (Miyaki et al. 1999). Huang et al. (1996) have demonstrated that 
the mononucleotide tracts within the APC gene are frequently mutated in MSI 
colorectal cancers. However, other studies on HNPCC-related CRCs have not 
confirmed this result but suggest that the mutational spectrum in HNPCC-CRCs 
is similar to that in sporadic tumors (Konishi et al. 1996; Akiyama et al. 2000). 
Mutations in APC can be found only in 21% of MSI tumors (Konishi et al. 1996; 
Akiyama et al. 2000), which is significantly less than in sporadic colon carcinomas 
(Miyaki et al. 1994). Besides APC, other target genes in the Wnt signaling pathway 
which contain coding microsatellite repeats are AXIN2 and TCF4 (Duval et al. 
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1999a; Liu et al. 2000). AXIN2 has been shown to be mutated in 25% of mismatch 
repair-deficient colon tumors (Liu et al. 2000). TCF4 is the predominant TCF 
family member expressed in the colonic epithelium (Korinek et al. 1997) and in 
MSI CRCs, mutations of the poly(A)9 coding repeat in TCF4 gene are relative 
frequent (~40%) (Duval et al. 1999b). 
Tumor progression in HNPCC-related endometrial cancer 
Relatively little is known about the molecular events that lead to the development 
of HNPCC-related endometrial cancer. Interestingly, the risk for development of 
EC seems to vary according to the predisposing mutation. It has been suggested 
that the lifetime risk for EC is higher in MSH2 mutation carriers than in MLH1 
mutation carriers, whereas the risk for CRC is similar (Vasen et al. 1996). 
Furthermore, MSH6 mutation carriers remarkably often display endometrial 
carcinoma (Miyaki et al. 1997; Wijnen et al. 1999). 
 
Complex atypical hyperplasia (CAH) is the premalignant lesion of uterine 
endometrioid carcinoma, the most prevalent type of endometrial cancer (Sherman 
and Brown 1979; Kurman et al. 1985). It appears to proceed in a stepwise fashion 
to the carcinoma stage (Cohn et al. 2001). This premalignant precursor, like 
adenoma in the colon, provides the opportunity to investigate the timing of 
specific genetic alterations that contribute to endometrial tumor progression. 
 
MMR deficiency is an early event in HNPCC-related endometrial tumorigenesis, 
which has been demonstrated by immunohistochemical analyses using antibodies 
directed against the MMR proteins and by MSI studies in CAHs from HNPCC 
patients (de Leeuw et al. 2000). The variation in the extent and level of MSI 
accounts for the differences in the age of onset. For example, the high frequency of 
MSI in CAHs has been observed only in MSH2 mutation carriers, which seems to 
correlate with an early age of cancer onset and thus indicates rapid tumor 
progression (de Leeuw et al. 2000). Slower tumor progression has been observed 
in MSH6 mutation carriers (Miyaki et al. 1997; Wijnen et al. 1999). Their tumors 
show a low frequency of MSI affecting mainly mononucleotide repeat tracts, 
which is a possible explanation for the slow tumor progression and late age of 
onset (de Leeuw et al. 2000). Furthermore, many endometrial carcinomas from 
MSH6 mutation carriers show instability at the (C)8 repeat within the MSH6 gene 
(Akiyama et al. 1997; Miyaki et al. 1997; Wijnen et al. 1999; de Leeuw et al. 2001), a 
site which is a rare target for MSH2 and MLH1 mutation carriers or sporadic EC 
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cases (Gurin et al. 1999). This significantly high frequency of instability at the (C)8 
repeat is suggested to contribute to bi-allelic inactivation of the MSH6 gene (de 
Leeuw et al. 2001).  
 
The most common target gene of the microsatellite mutator pathway in HNPCC-
ECs is PTEN (Kuismanen et al. 2002; Zhou et al. 2002). The BAX gene is affected in 
19% of HNPCC-ECs (de Leeuw et al. 2000; Kuismanen et al. 2002). Mutations in 
the K-ras oncogene and PTEN tumor suppressor gene are the only genetic 
alterations that have already been described in CAHs suggesting that their 
inactivation occurs early in endometrial tumorigenesis (Enomoto et al. 1991; 
Sasaki et al. 1993; Levine et al. 1998; Maxwell et al. 1998; Mutter et al. 2000). The 
mutation frequency of both genes is similar irrespective of the MSI status in 
sporadic endometrial cancers (Gurin et al. 1999; Swisher et al. 1999; Cohn et al. 
2000; Mutter et al. 2000). In most MSI cases, MMR deficiency appears to precede 
alterations in K-ras (Cohn et al. 2001). All somatic PTEN alterations found from 
HNPCC patients with MSH2 or MLH1 germline mutations are proved to be 
frameshift mutations affecting two (A)6 repeat tracts (Zhou et al. 2002). It is quite 
obvious that this instability is a consequence of MMR deficiency. Inactivation of 
PTEN appears to be involved in the initial stages of tumor development and also 
in endometrial tumor progression. Mouse studies also support the fundamental 
role for PTEN in the control of endometrial epithelial growth and proliferation 
(Wang et al. 2002). 
 
The role of the Wnt signaling pathway is unclear in HNPCC-EC tumorigenesis. 
The combination of MMR deficiency and APC hypermethylation is observed in 
sporadic ECs (Zysman et al. 2002), and the activating β-catenin mutations occur in 
10-30% of sporadic endometrial cancers (Fukuchi et al. 1998; Palacios and 
Gamallo 1998; Kobayashi et al. 1999; Schlosshauer et al. 2000; Machin et al. 2002). 
Interestingly, Persad et al. (2001) have described that PTEN also participates the 
regulation of β-catenin by inducing GSK-3β activity, which leads to increased 
phosphorylation of β-catenin and its subsequent degradation. PTEN inactivation 
and the occurrence of APC hypermethylation already in premalignant lesions 
suggest that aberrant Wnt signaling may present in the early stages of 
endometrial cancer development (Zysman et al. 2002).   
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AIMS OF THE PRESENT STUDY 
1) To address the question of whether and how MSH6 germline missense 
mutations cause susceptibility to HNPCC 
 
2) To determine by functional assay which one of the two germline MMR 
gene mutations, one in MSH6 and one in MSH2, found in an index patient 
could primarily underlie the cancer susceptibility in the family  
 
3) To study the molecular basis of organ selection in HNPCC by comparing 
the protein expression patterns of APC and β-catenin, the two widely 
expressed components of the Wnt signaling pathway, in HNPCC-related 
CRC and EC  
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MATERIALS AND METHODS 
Materials and methods are briefly described here. For details, see the original 
publications (I-IV). All investigations had approval from the appropriate 
institutional review boards. 
STUDY MATERIAL 
MSH6 and MSH2 missense mutations in studies I, II and III 
Altogether 11 MSH6 and one MSH2 germline missense mutations were included 
in the studies. Four analyzed MSH6 mutations were selected from the HNPCC 
database maintained by ICG/InSiGHT (http://www.nfdht.nl) (I). The remaining 
seven MSH6 mutations were novel and they were obtained from HNPCC 
researchers (II, III). The analyzed MSH2 mutation was previously reported in the 
mutation database. Two probands carried missense mutations in both MSH6 and 
MSH2 genes (II). Other probands were verified not to have germline mutations in 
MLH1 or MSH2 (I, III). Studied mutations were also excluded in 53-200 healthy 
controls. Analyzed mutations are listed in Table 4 and the locations of the 
mutated codons in the MSH6 protein are represented in Figure 5. 
 
Figure 5 Schematic representation of the MSH6 protein showing MSH6 missense 
alterations listed as pathogenic mutations in the mutation database (http://www.nfdht.nl), 
the mutations included in the present study (marked with bold letters) and functional 
domains in MSH6 (Guerrette et al. 1998; Iaccarino et al. 1998, 2000; Dufner et al. 2000; 
Kleczkowska et al. 2001).  
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Table 4 Studied missense mutations in MSH6 and MSH2 
Exon Codon Nucleotide 
change 
Effect Side chain changes of 
amino acid 
Conserved 
codona 
Ref 
MSH6 mutation 
2 128 CGT→CTT at 
383 
Arg→Leu basic→nonpolar 
 
No III 
2 144 AGC→ATC 
at 431 
Ser→Ile uncharged 
polar→nonpolar 
Yes Kolodner 
et al. 
1999; Wu 
et al. 
1999; 
Berends 
et al. 
2002 
4 566 GGA→AGA 
at 1696 
Gly→Arg nonpolar→basic Yes Kolodner 
et al. 
1999 
4 623 CCC→CTC 
at 1868 
Pro→Leu nonpolar→nonpolar No III 
4 728 AAA→ACA 
at 2183 
Lys→Thr basic→uncharged polar Yes III 
4 881 GGT→AAAAGT 
at 2641 
Gly→Lys+Ser nonpolar→basic+ 
uncharged polar 
No III 
5 1087 CCC→ACC 
at 3259 
Pro→Thr nonpolar→uncharged 
polar 
No Kolodner 
et al. 
1999 
5 1087 CCC→CGC 
at 3260 
Pro→Arg nonpolar→basic No Wijnen et 
al. 1999 
5 1095 CGC→CAC 
at 3284 
Arg→His basic→basic Yes II 
7 1193 GAA→AAA 
at 3577 
Glu→Lys acidic→basic Yes III 
10 1354 CTG→CAG 
at 4061 
Leu→Gln nonpolar→uncharged 
polar 
No II 
MSH2 mutation 
3 145 ATT→ATG 
at 435 
Ile→Met nonpolar→nonpolar Yes II 
aConserved between human and yeast (S. cerevisiae) 
 
Clinical data of the families and tumors included in studies I, II and III 
None of the 15 families, in which the 11 MSH6 mutations were found, fulfilled the 
Amsterdam criteria (I or II, Table 2) (Vasen et al. 1991, 1999) and they were 
classified as putative HNPCC families and named as Fam-MSH6-1-15. The 
mutation MSH6-S144I was detected in four different families (Fam-MSH6-2,3,4,5) 
(Kolodner et al. 1999, Wu et al. 1999, Berends et al. 2002)(I) and MSH6-E1193K 
was detected in two different families (Fam-MSH6-13,14) (III). Four families 
(Fam-MSH6-1,4,5,14) showed no family history of  carcinomas. Seven probands 
had endometrial cancer (EC) and eight probands had colorectal cancer (CRC). The 
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probands’ mean age at diagnosis was 59 years; the mean age of EC onset was 60 
years and CRC onset 57 years. The number of affected family members ranged 
from 0 to 3 and their mean age at onset was 63 years. Nine of the ten first degree 
relatives had CRC and their mean age of onset was as high as 67 years. The 
pedigrees of the families are shown in Figure 6. Microsatellite instability and 
immunohistochemical data of the probands’ tumors are shown in Table 5.  
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Figure 6 Pedigrees of the families with putative HNPCC and MSH6 missense mutations. 
A square represents a male; circle, female; diamond, unspecified gender; diagonal stripe, 
deceased; white symbols, not affected; black symbols, affected; arrow, mutation carrier. 
The probands in Fam-MSH6-12 and Fam-MSH6-15 also carried MSH2 mutation. Tumor 
types and ages at onset are marked. Abbreviations of the tumor types: BRC, breast 
cancer; CAH, complex atypical hyperplasia; CRA, colorectal adenoma; CRC, colorectal 
cancer; EC, endometrial cancer; LU, lung cancer; PR, prostate cancer; SK, skin cancer. 
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Tissue samples in study IV 
The colorectal and endometrial tumors were collected from a series of well-
characterized HNPCC families with segregating germline mutations in the 
mismatch repair genes MLH1 or MSH2 (Nyström-Lahti et al. 1996; Holmberg et 
al. 1998). The analysis of APC and β-catenin expression patterns included 31 
colorectal and 19 endometrial cancers from patients carrying the same 
predisposing mutations.  
 
METHODS 
All the methods used in studies I-IV are listed in Table 6. Cell lines used in the 
production of recombinant proteins and in an in vitro MMR assay are listed in 
Table 7 (I, II, III). Table 8 describes the antibodies used in Western blot, 
coimmunoprecipitation (I, II, III) and immunohistochemical analyses (IV). Table 
9 represents experimental conditions for the site-directed mutagenesis used in 
studies I, II and III. 
Table 6 Methods used in the studies 
Methods More information Used in 
Coimmunoprecipitation Table 8, used antibodies I, II, III 
DNA cloning and subcloning  I, II, III 
DNA heteroduplex preparation  I, II, III 
Immunohistochemistry Table 8, used antibodies IV 
In vitro MMR assay Table 7, used cell lines I, II, III 
PCR Table 9, used primers I, II, III 
Production of recombinant baculoviruses Table 7, used cell lines I, II, III 
Production of recombinant proteins Table 7, used cell lines I, II, III 
Site-directed mutagenesis Table 9, experimental conditions I, II, III 
Transfection  I, II, III 
Western blotting Table 8, used antibodies I, II, III 
 
Table 7 Cell lines used in the studies 
Cell line Description Source Used in 
HCT15 (DLD1) human colorectal adenocarcinoma cells (MSH6-/-) ATCC I, II, III 
Lovo human colorectal adenocarcinoma cells (MSH2-/-) ATCC II 
Sf9 Insect (Spodoptera frugiperda) cells Gibco BRL I, II, III 
TK6 human lymphoblasts ATCC I, II, III 
ATCC, American Type Culture Collection (USA) 
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Table 8 Antibodies used in the studies 
Antigen Description Source Used in 
APC mouse mAb (clone c-APC 28.9) against the C-
terminal fragment of human APC 
Abcam IV 
β-Catenin mouse mAb (clone 14) against the C-terminal 
fragment (amino acids 571-781) of human β-catenin 
BD Transduction 
Laboratories 
IV 
MSH6 mouse mAb (clone 44) against the N-terminal 
fragment (amino acids 225-333) of human MSH6 
BD Transduction 
Laboratories 
I, II, III 
MSH2 mouse mAb (clone GB12, Ab-1) against the N-
terminal fragment of human MSH2 
Calbiochem I, II, III 
mAb, monoclonal antibody 
 
 
Table 9 Experimental conditions for the site-directed mutagenesis (I, II, III) 
Mutation Oligos for fragments A and B in 1st PCR (5’→3’) 
(the mutated site is marked with bold letter and 
shaded background) 
Size 
(bp) 
Oligos 
for 2nd 
PCR 
Size 
(bp) 
Cloning
site 
MSH6-R128L FA: CGGATTATTCATACCGTCCC 
RA: CTGTACATGAACAAGGACTGATTTCCC 
FB: GGGAAATCAGTCCTTGTTCATGTACAG 
RB: GCCACCACTTCCTCATCC 
435 
 
874 
FA 
RB 
1282 BamHI 
Eco81I 
MSH6-S144I FA: CGGATTATTCATACCGTCCC 
RA: GCTTTAAAAGCCTTTTGATAACCCAGCCC 
FA: GGGCTGGGTTATCAAAAGGCTTTTAAAGC 
RA: GCCACCACTTCCTCATCC 
487 
 
824 
FA 
RB 
1282 BamH1 
Eco81I 
MSH6-G566R FA: GATGAGCACAGGAGGAGGC  
RA: CTATGAAAAACTTTCTCAGTGAAGTATC 
FB: GATACTTCACTGAGAAAGTTTTTCATAG 
RB: CCATCGGTTCAATTCTACAGTC 
574 
 
1053 
FA 
RB 
1599 Eco81I 
Pst1 
MSH6-P623L FA: GATGAGCACAGGAGGAGGC 
RA: CAAAACTGGGAGCCGAGTATCAGACCTTC 
FB: GAAGGTCTGATACTCGGCTCCCAGTTTTG 
RB: CCATCGGTTCAATTCTACAGTC 
746 
 
882 
FA 
RB 
1599 Eco81I 
PstI 
MSH6-K728T FA: GATGAGCACAGGAGGAGGC 
RA: CGTTGATAGGCTGTGGTGAAGATAGC 
FB: GCTATCTTCACCACAGCCTATCAACG 
RB: CCATCGGTTCAATTCTACAGTC 
1058 
 
567 
FA 
RB 
1599 Eco81I 
PstI 
MSH6-G881K+S FA: GATGAGCACAGGAGGAGGC 
RA: AGACTTAAAACTTTTATCAGCAACTTC 
FB: GAAGTTGCTGATAAAAGTTTTAAGTCT 
RB: CCATCGGTTCAATTCTACAGTC 
1518 
 
111 
FA 
RB 
1602 Eco81I 
PstI 
MSH6-P1087T FA: GTCTAAAATCCTTAAGCAGG 
RA: GCTCTAAGAAGGTGGGGGTATCTTCCG 
FB: CGGAAGATACCCCCACCTTCTTAGAGC 
RB: CTGATTATGATCCTCTAGTAC 
623 
 
1016 
FA 
RB 
1612 PstI 
XhoI 
MSH6-P1087R FA: GTCTAAAATCCTTAAGCAGG 
RA: GCTCTAAGAAGCGGGGGGTATCTTCCG 
FB: CGGAAGATACCCCCCGCTTCTTAGAGC 
RB: CTGATTATGATCCTCTAGTAC 
623 
 
1016 
FA 
RB 
1612 PstI 
XhoI 
  Table 9 continues on page 44 
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Table 9 continued from page 43     
MSH6-R1095H FA:GTCTAAAATCCTTAAGCAGG 
RA: GCAAGGATGGTGTGATCCTTTAAGC 
FB: GCTTAAAGGATCACACCATCCTTGC 
RB: CTGATTATGATCCTCTAGTAC 
646 
 
991 
FA 
RB 
1612 Pst1  
Xho1 
MSH6-E1193K FA: GTCTAAAATCCTTAAGCAGG 
RA: GTTTCACTTAATTTAACAAAAAATGTAC 
FB: GTACATTTTTTGTTAAATTAAGTGAAAC 
RB: CTGATTATGATCCTCTAGTAC 
942 
 
698 
FA 
RB 
1612 PstI 
XhoI 
MSH6-L1354Q FA: GTCTAAAATCCTTAAGCAGG 
RA: CCTTAATCAAAGTCTGCAATTTATGGAC 
FB: GTCCATAAATTGCAGACTTTGATTAAGG 
RB: CTGATTATGATCCTCTAGTAC 
1427 
 
213 
FA 
RB 
1612 PstI 
XhoI 
MSH2-I145M FA: CGGATTATTCATACCGTCCC 
RA: CACCCACAACACCCATGGAAGCTGAC 
FB: GTCAGCTTCCATGGGTGTTGTGGGTG 
RB: ATCTTGAACTTCAACACAAGC 
534 
 
1516 
FA 
RB 
2024 BamH1  
Nde1 
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RESULTS 
FUNCTIONALITY OF MSH6 AND MSH2 PROTEIN VARIANTS (I, II, III) 
Missense mutations were introduced into MSH6 or MSH2 cDNAs using PCR-
based site-directed mutagenesis and the products were cloned into the plasmid 
pFastBac1. The cloned mutant fragments were verified by DNA sequencing. The 
recombinant baculoviruses were used as expression vectors and they were 
transfected into Sf9 insect cells. For protein production, insect cells were always 
co-infected with MSH2 and MSH6 recombinant baculoviruses, since both in vivo 
studies in mice (de Wind et al.  1999) and in vitro studies in human cells (Marra et 
al. 1998; Chang et al. 2000) have shown that the MSH6 protein is unstable in the 
absence of its partner MSH2. After 72 hours of culture, the total protein extracts, 
including the overexpressed MSH6 and MSH2 proteins, were prepared. 
Western blot and interaction analyses of the MSH6 variants with 
wildtype MSH2 (I, II, III) 
The total protein extracts from Sf9 insect cells were investigated by Western blot 
and coimmunoprecipitation analyses to study the effect of the mutations on the 
protein expression level and on the MSH2-MSH6 (MutSα) interaction. In Western 
blotting, the amount of the wildtype (WT) MSH2 protein was adjusted to be 
equal in different extracts in order to see a variation in the MSH6 expression 
level. In coimmunoprecipitation analysis, MSH6 protein was specifically 
immunoprecipitated from the total protein extract using the antibody against it. 
MSH6 and coprecipitated MSH2 proteins were resolved on a polyacrylamide gel 
and detected by Western blotting. The purified MutSα complex and the wildtype 
MutSα total protein extract were used as controls. 
 
The MutSα-WT and ten out of eleven MutSα-variants contained similar amounts 
of MSH2 and MSH6 proteins in total protein extracts. In the extract MutSα-
G566R, the amount of the MSH6 protein was clearly reduced (I: Figure 1). The 
reduction of this variant was observed even if twice the normal amount of the 
recombinant MSH6-G566R baculovirus was used for transfection and the amount 
of MSH2 kept normal. However, the mutation did not abolish the MSH2-MSH6 
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interaction. All the studied MSH6 variants interacted normally with MSH2-WT 
excluding MSH6-E1193K, which coprecipitated clearly less MSH2-WT than 
MSH6-WT (III: Figure 1A). 
Western blot and interaction analyses of the MSH2 variant with 
wildtype MSH6 and with the MSH6 variants (II) 
In study II, we described two colon cancer families in which the probands 
carried missense mutations in both MSH2 and MSH6 genes. The MSH2 mutation, 
MSH2-I145M, was the same in both families, whereas the MSH6 mutations were 
different (MSH6-R1095H and MSH6-L1354Q). The same functional analyses as in 
studies I and III were performed to determine which one of the mutations could 
primarily underlie the cancer susceptibility in these families.  
 
The MSH2-I145M variant repeatedly showed a large amount of protein in co-
expression with MSH6-WT in contrast to coexpression with either of the two 
mutated MSH6 proteins. Furthermore, when MSH2-I145M/MSH6-WT total 
protein extract was coimmunoprecipitated with anti-MSH6 antibody, the ratio of 
the amount of precipitated MSH2 to the amount of precipitated MSH6 was 
clearly increased when compared to the ratio of MSH2 to MSH6 in the wildtype 
control extract or in the mutated extracts. However, none of the mutations 
abolished the MSH2-MSH6 interaction (II: Figure 2).  
Mismatch repair capability of MutSα heterodimers (I, II, III)  
According to coimmunoprecipitation analysis, none of the studied mutant 
proteins entirely abolished the MSH2-MSH6 interaction. In order to find out if 
the mutations could still be responsible for the MMR-defect (I, III), and in study 
II to further clarify which one of the two mismatch repair gene mutations might 
contribute to cancer susceptibility, the recombinant MutSα variants were tested 
in an in vitro MMR assay. In the assay, the total protein extract from baculovirus-
infected Sf9 cells, which contained the overexpressed recombinant MutSα 
variant, was incubated together with nuclear extract (NE) from a mismatch 
repair-deficient cell line lacking functional MSH6 or MSH2 protein. The repair 
reaction was carried out using a nicked circular heteroduplex molecule, which 
contains a G•T mismatch, as the substrate (Lu et al. 1983; Lahue et al. 1989; 
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Holmes et al. 1990). If the MutSα variant can correct the mismatch a specific 
restriction enzyme is able to cut the heteroduplex, so that the repair efficiency 
can be estimated at the conclusion of the repair reaction. Since the heteroduplex 
DNA molecules are not all repairable, they are added in excess and the 
percentage of repaired molecules in the proficient wildtype controls are used as a 
reference level.  
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Figure 6 Mismatch repair activity of MMR-deficient HCT15 (MSH6-/-) and Lovo     
(MSH2-/-) nuclear extracts (NEs) complemented with MutSα variants (above). Mock (lane 
1), heteroduplex DNA with no protein used as a negative control; TK6 (lane 2), MMR-
proficient NE used as a positive control; HCT15 (H) (lane 3) and Lovo (L) (lane 17) are 
MMR-deficient NEs used as negative controls. The repair efficiencies are represented as 
repair percentages (the proportion of repaired DNA of the total DNA added to the 
reaction). 
As represented in Figure 6, the negative controls, mock, and NEs from the 
HCT15 (MSH6-/-) and Lovo (MSH2-/-) cells, were not able to repair the G•T 
mismatch. The positive control, NE from MMR-proficient TK6 cells, repaired 
42% of the heteroduplex DNA. Also the purified MutSα and MutSα-WT total 
extract were able to complement the MSH6-deficient NE of HCT15 and MSH2-
deficient NE of Lovo cells and repaired approximately 30% of heteroduplex 
DNA. Interestingly, ten of eleven studied MSH6 mutant variants were proficient 
in the assay. MutSα-R128L, MutSα-S144I, MutSα-G566R, MutSα-P623L, MutSα-
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K728T, MutSα-G881K+S, MutSα-P1087T, MutSα-P1087R, MutSα-R1095H and 
MutSα-L1354Q repaired 41%, 31%, 30%, 39%, 41%, 41%, 32%, 34%, 30% and 31% 
of G•T heteroduplexes, respectively. MutSα-E1193K failed to repair mismatches 
and displayed complete MMR deficiency (0%). The Sf9 extracts including the 
mutated MSH2 with wildtype MSH6 (MutSα-I145M) or with the mutated MSH6 
proteins (MutSα-R1095H/I145M and MutSα-L1354Q/I145M) were all proficient in 
the MMR assay. They were able to complement both MSH2-deficient and MSH6-
deficient NEs, repairing approximately 32% of G•T molecules. The repair 
percentage values are an average of at least two independent experiments. 
 
Table 10 summarizes the functionality of the studied MSH6 and MSH2 protein 
variants.  
Table 10 The results of the functional tests. 
 MSH6 variants MSH2 variant/ 
MSH6 variants 
 R128L S144I G566R P623L K728T G881K+S P1087T P1087R E1193K MSH2-
I145M/ 
MSH6-
R1095H 
MSH2-
I145M/ 
MSH6-
L1354Q 
Protein 
expression 
Normal Normal Decreased Normal Normal Normal Normal Normal Normal Normal Normal 
MutSα 
interaction 
Normal Normal Normal Normal Normal Normal Normal Normal Decreased Normal Normal 
MMR 
capability 
Normal Normal Normal Normal Normal Normal Normal Normal Decreased Normal Normal 
 
 
APC AND β-CATENIN EXPRESSION PATTERNS IN HNPCC-RELATED 
COLORECTAL AND ENDOMETRIAL CARCINOMAS (IV) 
The molecular basis of organ selection in HNPCC is poorly understood. 
Overactivation of the Wnt signaling pathway has been shown to play an 
important role in tumorigenesis of CRCs, including HNPCC-related CRCs, as 
well as sporadic ECs, but HNPCC-ECs are poorly characterized in this regard. 
The overactivation of the pathway is mostly a consequence of mutations in the 
APC or β-catenin genes (Miyaki et al. 1999; Akiyama et al. 2000). The pathological 
impact of these mutations can be demonstrated by immunohistochemical 
staining of β-catenin protein, which is present in the nucleus only if the Wnt 
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signaling pathway has been activated due to the inactivation of APC or 
alterations in the β-catenin gene itself (Morin et al. 1997; Rubinfeld et al. 1997; 
Fukuchi et al. 1998; Palacios and Gamallo 1998; Sparks et al. 1998; Kobayashi et 
al. 1999; Mirabelli-Primdahl et al. 1999; Iwamoto et al. 2000). Thus, in tumor 
tissue, where APC immunoreactivity is absent, β-catenin staining can be seen in 
the nucleus. In normal colonic mucosa and in normal epithelium of the 
endometrium, β-catenin expression is seen at the plasmamembrane (Fukuchi et 
al. 1998; Iwamoto et al. 2000; Hao et al. 2002).  
 
To clarify the molecular basis of organ selection in HNPCC, we 
immunohistochemically compared APC and β-catenin expression patterns in 31 
HNPCC-CRCs and 19 HNPCC-ECs. Tumor samples were derived from patients 
carrying the same predisposing mismatch repair gene mutations in either MLH1 
or MSH2. Tumors were considered positive for APC if staining was present in > 
10% of tumor cells and negative if there was staining in < 10% of tumor cells 
accompanied by positive staining of the matching normal tissue. Tumors 
showing any nuclear staining for β-catenin were classified as nuclear. 
APC and β-catenin protein expression in HNPCC-related CRCs and ECs 
Loss of APC expression was observed in 39% of CRCs (12 /31) and in 16% of ECs 
(3/19). All negative CRC tumors were from HNPCC patients carrying MLH1 
mutations. Two negative EC tumors were from MLH1 mutation carriers and one 
was from a MSH2 mutation carrier. All APC negative tumors showed nuclear β-
catenin staining. Overall, nuclear β-catenin expression was observed in 84% of 
CRCs (26/31) and in 53% of ECs (10/19). Our series comprised three tumors from 
MSH2 mutation carriers, and two of them showed normal β-catenin expression. 
Immunohistochemical results from each HNPCC patient are described in detail 
in Table 11. 
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Table 11 APC and β-catenin expression in HNPCC-related colorectal and endometrial 
cancers 
HNPCC-CRC              HNPCC-EC 
ID Muta APCb β-cateninc 
M           C              N 
 ID Muta APCb β-cateninc 
  M             C              N 
1:32 1 +  - ++  -  2:51 1 + - + ++ 
1:49 1 + - +++  +++   3:5 1 + ++ + - 
2:6 1 - - ++ +++   11:33 1 + ++ - - 
2:67 1 - - +++  +++   19:48 1 - - ++ ++ 
3:9 1 + - +++  +++   30:36 1 + ++ - - 
10:6 1 - - - +++   43:23 1 - - +++  +++  
11:9 1 + - ++ +  66:47 1 + ++ - - 
11:13 1 - - +++  +  82:9 1 + - ++  +++  
19:48 1 + - ++ ++  99:13 1 + ++ ++ - 
43:23 1 + +++  - -  7:18  3 + +++  - + 
50:45 1 - - ++  +++   28:11 5 + ++ - - 
54:84 1 + ++ - -  67:31 5 + + ++ ++ 
59:11 1 + + + -  105:9 5 + ++ - - 
60:5 1 + - +++  +++  39:19 6 + +++ - - 
66:47 1 + - +++  +++   39:50 6 + - +++ +++  
82:10 1 - - +++  +++   40:9 7 +  +++  - - 
99:9 1 - + + +  83:11 8 + +++  - - 
26:9 2 - - ++  +++   93:7 9 - + + +++  
29:26 2 - - ++ +++   93:27 9 + ++ - - 
61:44 2 + + + - 
90:15 2 + - ++  ++ 
91:20 2 + - +++  +++  
90:29 2 + + - - 
7:20 3 - +++  +++  + 
67:11 5 + - ++ +++  
39:50 6 - - + ++ 
40:9 7 - - ++ ++ 
72:5 8 + - ++  +++  
38:8 9 + ++ - - 
93:4 9 + - ++  +++  
93:30 9 + +++  - - 
a Mutations 1-8 affect MLH1 while mutation 9 affects MSH2 (Holmberg et al. 1998; NystromLahti et al. 1996) 
bTumors were considered positive (+) for APC if staining was present in > 10% of tumor cells and negative 
(-) for APC if there was staining in <10% of tumor cells accompanied by positive staining in > 10% of the 
matching normal tissue 
c Tumors showing any nuclear staining for β-catenin were classified as nuclear (N). C, cytoplasmic; M, 
membranous. The intensity of β-catenin staining was graded as weak (+), intermediate (++) or strong (+++).  
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DISCUSSION 
PATHOGENICITY OF INHERITED MISSENSE ALTERATIONS IN THE 
MMR GENE, MSH6 (I, III) 
Germline mutations in four different MMR genes, MSH2, MLH1, MSH6 and 
PMS2, are associated with HNPCC. A great proportion of all mutations 
identified in MMR genes are of the missense type, the consequences of which are 
difficult to interpret (http://www.nfdht.nl). Especially the pathogenicity of 
mutations in MSH6, the third most common suscebtibility gene in HNPCC 
syndrome, often remains questionable, because they are mainly linked to 
putative HNPCC families with atypical clinical characteristics such as a late age 
of onset, few affected family members, a tumor spectrum with an excess of 
endometrial cancers and a lack of or low MSI phenotype (Kolodner et al. 1999; 
Wijnen et al. 1999; Wu et al. 1999; Parc et al. 2000; Wagner et al. 2001).  
 
The main aim of this thesis was to elucidate whether and how MSH6 missense 
mutations cause cancer susceptibility (I, III). The pathogenicity of HNPCC 
germline mutations is associated with malfunction of the DNA mismatch repair 
reaction, which leads through the microsatellite mutator pathway to tumor 
formation. To clarify the role of MSH6 missense mutations in this context, we 
selected to study alterations which fulfilled at least two of the following criteria 
supporting their assumed pathogenicity: (1) the mutated codon was located in an 
evolutionarily conserved residue (Table 4 in page 39); (2) the amino acid 
substitution was significant, for example changing its polarity (Table 4 in page 
39); (3) the mutation was not present in healthy control individuals and (4) MSH2 
and MLH1 germline mutations were excluded.  
 
The nine MSH6 missense mutations included in the studies were found in 13 
putative HNPCC families (Figure 6 in page 40), none of which fulfilled the 
Amsterdam criteria I or II (Vasen et al. 1991, 1999). Five MSH6 variations were 
derived from the series of consecutive EC and CRC patients selected for study 
after their tumors were determined to be microsatellite unstable. Irrespective of 
the MSI phenotype in their tumors, none of the mutation carriers had first-degree 
relatives with EC or CRC or any family history of cancer suggestive of HNPCC 
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(III). Four studied variants, listed as pathogenic mutations in the mutation 
database, were identified from non-HNPCC or suspected HNPCC families 
comprising only few affected family members with a late age of onset, which are 
uncharacteristic features of HNPCC (I) (Kolodner et al. 1999; Wijnen et al. 1999; 
Wu et al. 1999; Berends et al. 2002). Segregation studies to distinguish pathogenic 
missense alterations from nonpathogenic variation were not available from any 
families under scrutiny. The studies were hindered by insufficient family size or 
unavailability of specimens. Microsatellite instability data was available in 10 out 
of 13 studied tumors (Table 5 in page 41). Four tumors showed a MSI low 
phenotype and six showed a MSI high phenotype. This indicates that the 
majority of studied tumors were MMR-deficient. Three out of four MSI-low 
tumors and four out of six MSI-high tumors were endometrial cancers, 
suggesting that the MSI phenotype was not restricted to tumor type. 
Immunohistochemical staining results of the MMR proteins MLH1, MSH2, 
MSH6 and PMS2 were available in 8 out of 13 studied tumors (Table 5 in page 
41). In immunohistochemical analysis, it is important to note that even if the 
amino acid substitution is pathogenic the mutation does not necessarily lead to 
loss of the protein. On the other hand, alterations in MMR proteins can prevent 
heterodimerization so that the unstable partner of the complex (MSH6, MSH3, 
PMS2) may be absent or present only in a low concentration in the tumor tissue 
(Marra et al. 1998; de Wind et al. 1999; Räschle et al. 1999; Chang et al. 2000). 
 
Here, the pathogenicity of MSH6 missense mutations was evaluated by studying 
their effect on the overall protein expression level, the MSH2-MSH6 protein 
interaction, and on the mismatch repair capability of MSH2-MSH6 (MutSα) 
heterodimers. The Baculovirus expression system was used to produce MutSα 
variants in cultured insect cells. The MSH2-MSH6 protein interaction was 
studied with a coimmunoprecipitation assay by using the anti-MSH6-antibody to 
coprecipitate MSH2 protein. The MMR capability of MutSα heterodimers was 
resolved in the human cell-based in vitro MMR assay (Lahue et al. 1989; Holmes 
et al. 1990; Nyström-Lahti et al. 2002). By using a cell line (HCT15) that has 
defective MutSα but functional MutSβ (MSH2-MSH3), and a heteroduplex with a 
base-base mismatch as a substrate, we were able to study the functionality of 
MSH6 variants in MMR.  
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Eight out of nine studied MSH6 missense mutations showed no impairment in 
our functional tests, while one mutation, MSH6-E1193K, displayed marked 
impairment of both the MSH2-MSH6 interaction and mismatch repair function 
(I, III). Compared to MSH6 wildtype protein, the MSH6-E1193K variant 
coprecipitated clearly less MSH2, and the heterodimer MutSα-E1193K showed a 
defect in mismatch repair. This mutation occurred in two women with 
endometrial cancer (ages at onset 59 and 60 years). Both tumors showed a lack of 
mutated MSH6 protein. This observation was compatible with MMR deficiency 
and the MSI phenotype associated with this mutation. The substitution in the 
conserved codon 1193 was dramatic since amino acid alteration from negatively 
charged glutamate to positively charged lysine changes the polarity of the amino 
acid. This codon is further located in a highly conserved region between the ATP 
and Mg2+ binding sites (Iaccarino et al. 1998, 2000; Dufner et al. 2000) (Figure 5 in 
page 38) and could accordingly be expected to be sensitive to alterations. 
However, irrespective of the MMR deficiency associated with the MSH6-E1193K 
mutation, it occurred in probands who showed no family history of cancer 
suggestive of HNPCC (III). 
 
Two mutations, MSH6-S144I and MSH6-G566R, had previously been studied in 
the Saccharomyces cerevisiae –based functional assay and suggested to be loss-of-
function and partial loss-of-function mutations, respectively (Kolodner et al. 
1999). In our assay, both protein variants MutSα-S144I and MutSα-G566R 
repaired mismatches as efficiently as wildtype MutSα and MSH6-S144I showed 
no impairment of expression level or heterodimerisation with MSH2 protein. 
However, MSH6-G566R was the only variant among the studied MSH6 variants 
that showed a markedly decreased expression level compared to the expression 
level of wildtype MSH6 protein, suggesting problems with its stability. The 
colorectal carcinoma from the MSH6-G566R mutation carrier was reported to 
have a high MSI status, but in that case the immunohistochemistry was not done 
to confirm that the high MSI phenotype was specifically linked to the 
inactivation of MSH6 protein. We cannot exclude the possibility that 
pathogenicity of this mutation is caused by lower levels of functional MSH6 
protein, as has previously been shown to be the case with some MLH1 mutations 
(Raevaara et al. 2003). The codon G566 is located in one of the two MSH2-MSH6 
interaction regions (Figure 5 in page 38) (Guerrette et al. 1998). In 
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coimmunoprecipitation analysis the MSH6-G566R variant was still able to 
interact with MSH2 protein (I). 
 
The codon 1087 was interesting, since it is located in the (C)8 repetitive region in 
MSH6, frequently used as an MSI marker (Wijnen et al. 1999; Malkhosyan et al. 
1996). Many endometrial carcinomas have shown instability in that repeat region 
(Akiyama et al. 1997; Miyaki et al. 1997; Wijnen et al. 1999; de Leeuw et al. 2001). 
The significant frequency of instability at the (C)8 repeat is suggested to 
contribute to bi-allelic inactivation of the MSH6 gene (de Leeuw et al. 2001). We 
studied two substitutions in that region, MSH6-P1087T and MSH6-P1087R, and 
interestingly both variants were functional in the in vitro MMR assay (I). 
 
The three tumors, derived from the patients carrying the mutations MSH6-
R128L, MSH6-K728T and MSH6-G881K+S, which were MMR-proficient in our 
assay, expressed MSH6 but lacked MLH1 protein. Promoter hypermethylation of 
the MLH1 gene was observed in all these tumors, which might explain the 
inactivation of MLH1, and consequently the lack of MLH1 and high MSI 
phenotype in the tumors. Transcriptional silencing of MLH1 is frequently 
associated with somatic MMR defect and high MSI in sporadic colorectal 
carcinomas (Liu et al. 1995; Kane et al. 1997; Veigl et al. 1998; Esteller et al. 1999; 
Kuismanen et al. 2000). The mutation MSH6-P623L, which was also MMR-
proficient in our functional assay, was found in a patient whose EC showed high 
MSI and lack of MSH6, but positive staining for the MMR proteins MSH2, MLH1 
and PMS2, suggesting that loss of MSH6 was the reason for the MSI phenotype 
in the tumor (III).  
 
In summary, the human cell-based in vitro MMR assay investigates the 
phenotypic consequences of HNPCC mutations in a homologous human MMR 
system. Our results showed that under stable in vitro circumstances, when the 
amounts of the proteins are sufficient for repair, eight out of nine mutated MSH6 
proteins were as proficient as wildtype MSH6 protein in MMR reaction. 
However, the results do not exclude the possibility that the mutations can still 
have an effect, not directly on the repair function, but on earlier steps in vivo. 
Examples would be the instability of MSH6 mutant mRNA transcripts, instability 
of mutated MSH6 proteins or problems in nuclear localization. The MMR-
deficient missense variation, MSH6-E1193K, was derived from a family which 
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clinically resembles the other kindreds under study. Thus, this missense change 
seems to be clinically significant, but has low penetrance. Our results from the 
functional assay, together with the clinical data of the patients and their families, 
suggest that most missense changes in MSH6 cause no or low cancer 
susceptibility. Despite the limitations concerning the functional tests, they are the 
only way to distinguish pathogenic alterations from nonpathogenic variations 
especially in cases where segregation studies are not possible. Thus, functional 
tests are needed to confirm that cancer susceptibility in a family is indeed linked 
to a detected mutation. This is important in genetic counselling since it has to be 
based on a reliable assessment of the pathogenicity of the mutation.  
PATHOGENICITY OF TWO DIFFERENT MMR GENE MUTATIONS 
INHERITED IN A SINGLE COLON CANCER PATIENT (II) 
In study II, we described two colon cancer families in which the probands 
carried missense mutations in both the MSH2 and MSH6 genes. The MSH2 
mutation, MSH2-I145M, was the same in both families, whereas the MSH6 
mutations, MSH6-R1095H and MSH6-L1354Q, were different. The families did 
not fulfill the Amsterdam criteria I or II (Vasen et al. 1991, 1999). The mean age at 
colon cancer onset was as high as 67 years in Fam-MSH6-12 and 58 years in Fam-
MSH6-15. Colorectal tumors in both families displayed a MSI high phenotype. 
Despite the two susceptibility mutations in different MMR genes, these patients 
did not display a clinically more severe phenotype than heterozygous carriers in 
general, which is consistent with previous reports (Wu et al. 1999, 2001; 
Samowitz et al. 2001). Interestingly, all affected family members were in one 
generation in both families, which suggests a recessive rather than the dominant 
mode of inheritance characteristic of HNPCC (Figure 6 in page 40).   
 
We used the same methods as in studies I and III to clarify which one of the 
MMR gene mutations could primarily underlie the cancer susceptibility in the 
families. Our results showed that none of the three mutations, MSH2-I145M, 
MSH6-R1095H or MSH6-L1354Q, individually lead to a deficiency in MMR, but 
the results did not exclude the possibility that the two mutations together result 
in compound pathogenicity. MSH2 and MSH6 proteins function together as a 
heterodimeric complex that recognizes mismatches and small insertion/deletion 
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loops. This is in agreement with the idea of their compound pathogenicity. 
Because no cell line in which both MSH2 and MSH6 are inactivated is available, 
and since it has been demonstrated that the MSH6 protein is unstable without its 
partner MSH2 (Marra et al. 1998; Chang et al. 2000), we used nuclear extracts of 
MSH2-deficient LoVo cells to study the compound effect of the two mutations. 
However, even a small amount of natural MSH6 protein, which might have been 
present in the LoVo extract, could have interacted with free MSH2-I145M 
molecules with the result that the complemented LoVo extract was functional in 
the MMR assay.  
 
We also found that MSH2-I145M interacted more efficiently with wildtype 
MSH6 than with mutated MSH6 variants suggesting some kind of aggregation of 
MSH2-I145M molecules with MSH6-WT molecules. One of the three mutations, 
MSH6-L1354Q, is located in the MSH2-MSH6 interaction region in the extreme 
C-terminal part of the MSH6 polypeptide (Guerrette et al. 1998) (Figure 5 in page 
38). This mutated protein was still able to interact with wildtype MSH2 protein 
and was functional in the MMR test. 
 
To summarize, the mutations alone did not cause MMR deficiency in the 
families. In addition, the human cell-based in vitro MMR assay did not permit the 
clarification of the possible compound pathogenicity of the two mutations or the 
biochemical events preceding the MMR reaction (see above). Hence, the results 
of the test should always be interpreted together with clinical and genetic data of 
the families under study.  
APC/β-CATENIN INVOLVEMENT IN HNPCC-RELATED COLORECTAL 
AND ENDOMETRIAL CARCINOMAS (IV) 
The molecular basis of organ selection in HNPCC is poorly understood. It is 
known that the target gene pattern is more heterogenous and involves a lower 
proportion of unstable markers per tumor in HNPCC-ECs than HNPCC-CRCs 
despite the same predisposing MMR mutation in the patients (Kuismanen et al. 
2002). Some target genes of the microsatellite mutator pathway, such as IGFIIR, 
MSH3 and MSH6, seems to be fairly evenly involved in these tumors (de Leeuw 
et al. 2000; Kuismanen et al. 2002), whereas TGFβRII and PTEN show 
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considerable tissue specificity. (Konishi et al. 1996; Tannergård et al. 1997; 
Kuismanen et al. 2002; Paoloni-Giacobino et al. 2002; Zhou et al. 2002). The 
differences between affected target genes and their inactivation frequencies 
support the suggestion that tumor progression occurs via distinct mechanisms in 
these two organs (de Leeuw et al. 2000; Schweizer et al. 2001; Kuismanen et al. 
2002). We concentrated on comparing the involvement of APC and β-catenin, the 
two major components of the Wnt signaling pathway, in the tumorigenesis of 
HNPCC-related CRCs and ECs. The Wnt pathway is overactivated in 65% of 
HNPCC-CRCs (Miyaki et al. 1999), in about 90% of sporadic CRCs (Iwamoto et 
al. 2000; Hao et al. 2002) and in about 30% of sporadic ECs (Fukuchi et al. 1998; 
Palacios et al. 2001; Schlosshauer et al. 2002). However, in HNPCC-related ECs 
its role has not been determined.  
 
The overactivation of the Wnt pathway is mainly a consequence of mutations in 
the APC or β-catenin genes, but alterations in AXIN2 and TCF4, target genes of 
the microsatellite mutator pathway, have also been found in mismatch repair 
defective colon tumors (Miyaki et al. 1999; Akiyama et al. 2000; Duval et al. 
1999a; Liu et al. 2000). The pathological impact of these mutations can be 
demonstrated by immunohistochemical staining of β-catenin protein. In normal 
colonic mucosa and in normal epithelium of the endometrium, β-catenin 
expression can be seen at the plasmamembrane (Fukuchi et al. 1998; Iwamoto et 
al. 2000; Hao et al. 2002), where it is bound to E-cadherin and α-actin, mediating 
the connection of cadherin cell adhesion molecules to the actin cytoskeleton 
(McCrea et al. 1991; Hulsken et al. 1994). The cytoplasmic concentration of free β-
catenin is very low due to its degradation by proteosomes in normal epithelial 
cells. Inactivation of APC leads to the accumulation of β-catenin in the cytoplasm 
and nucleus. In tumor tissue, where APC immunoreactivity is absent, β-catenin 
staining can be seen in the cytoplasm and nucleus (Iwamoto et al. 2000). 
Alterations in the β-catenin gene itself can also lead to its stabilization. In that 
case, mutations often occur in the regulatory domain (codons 29-48) in exon 3 of 
the β-catenin gene, which prevents its phosphorylation and degradation (Morin 
et al. 1997; Rubinfeld et al. 1997; Fukuchi et al. 1998; Palacios and Gamallo 1998; 
Sparks et al. 1998; Kobayashi et al. 1999; Mirabelli-Primdahl et al. 1999).  
 
Comparison between 31 CRCs and 19 ECs from HNPCC patients with similar 
predisposing germline mutations revealed differences in APC and β-catenin 
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expression. Tumor-specific loss of APC expression was always associated with 
nuclear β-catenin localization, suggesting deregulation of the Wnt signaling 
pathway. Our APC and β-catenin expression results in HNPCC-CRCs were 
consistent with studies of sporadic CRCs (Huang et al. 1996; Miyaki et al. 1999; 
Sparks et al. 1998; Mirabelli-Primdahl et al. 1999; Iwamoto et al. 2000; Hao et al. 
2002). This study did not aim to analyze the exact inactivation mechanism of 
APC. The frequency of somatic APC mutation is observed to be lower in 
HNPCC-CRCs (~20%) than in sporadic MSS colon tumors (>70%) (Miyaki et al. 
1994; Huang et al. 1996; Konishi et al. 1996), and no somatic APC mutations have 
so far been found in endometrial cancers (Schlosshauer et al. 2000; Moreno-
Bueno et al. 2002). We identified 16% (3/19) of EC tumors with loss of APC. This 
might be the first clear evidence of Wnt pathway involvement in endometrial 
tumorigenesis, since APC loss was associated with nuclear β-catenin localization. 
Previous studies of sporadic ECs that detected APC promotor hypermethylation 
(47%) and LOH at the APC locus (26%) showed that neither of these was 
associated with nuclear β-catenin (Moreno-Bueno et al. 2002). The frequency of 
nuclear β-catenin in HNPCC-ECs (53%) was consistent with sporadic ECs 
(Fukuchi et al. 1998; Palacios et al. 2001; Schlosshauer et al. 2002), but it was 
lower than what we observed in HNPCC-related CRCs (84%). We did not find 
any significant correlation between deregulation of the Wnt signaling pathway 
and a specific predisposing MMR gene mutation. 
 
Taken together, we showed that activation of the Wnt pathway, as judged by 
nuclear β-catenin expression, plays an important role in both colorectal and 
endometrial tumorigenesis. APC and β-catenin abnormalities in endometrial 
tumors are less frequent than in colon tumors even when the same mismatch 
repair gene mutation predisposed to both tumor types. 
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CONCLUSIONS  
1) In stable in vitro circumstances, when the amounts of the proteins are 
sufficient for repair, most MSH6 missense mutations are MMR-proficient 
2) In vivo MSH6 missense mutations may affect biochemical events 
preceding the MMR function, for example the pathogenicity of some 
MSH6 missense mutations can be linked to the shortage of functional 
protein 
3) Some missense changes in MSH6, which lead to impaired mismatch 
repair, are likely to be clinically significant, but can still have low 
penetrance 
4) Results of the functional assay together with the clinical data of the 
patients and their families suggest that most missense changes in MSH6 
cause no or low cancer susceptibility  
5) Especially in situations where cosegregation of a missense mutation and 
disease phenotype cannot be studied, a functional test is needed to 
confirm that cancer susceptibility in a family is linked to a detected 
mutation 
6) The human cell-based in vitro MMR assay can be used to resolve which 
one of the two MMR gene mutations found in the same patient is 
pathogenic, but compound pathogenicity of MSH2 and MSH6 mutations 
can not be studied by it because of the lack of a suitable cell line 
7) HNPCC-related endometrial cancers also progress through deregulated 
Wnt signaling. APC/β-catenin abnormalities in HNPCC-related ECs,  
although significant, are less frequent than in HNPCC-related CRCs even 
when the same mismatch repair gene mutation predisposed to both tumor 
types 
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FUTURE PROSPECTS 
To further explore how MSH6 missense mutations can cause cancer susceptibility 
it would be necessary 
1) To study the expression level and stability of the mutated MSH6 proteins 
in a homologous human expression system 
2) To study whether the MSH6 mutant mRNA transcripts are unstable  
3) To clarify if MSH6 variants have problems in nuclear transfer and 
localization 
 
To further clarify the molecular basis of organ selection and tumor progression in 
HNPCC, it would be required 
4) To clarify whether there are other gene defects in the Wnt signaling 
pathway that might substitute for β-catenin abnormalities, e.g. AXIN2  
5) To make larger-scale expression studies of the target tumor suppressor 
genes of the mutator pathway  
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